

---

# **Ohio Medicaid Fee-For-Service**

## **Pharmacy Benefit Management Program**

---

# **Preferred Drug List**



Effective November 1, 2013

**Ohio Department of Medicaid**

September 23, 2013

# Table of Contents

<b>Drug Category</b>	<b>Page</b>
Analgasic Agents: Gastroprotective NSAIDs .....	4
Analgasic Agents: Gout .....	5
Analgasic Agents: Opioids .....	6
Blood Formation, Coagulation, and Thrombosis Agents: Hematopoietic Agents .....	11
Blood Formation, Coagulation, and Thrombosis Agents: Heparin-Related Preparations .....	12
Blood Formation, Coagulation, and Thrombosis Agents: Oral Anticoagulants .....	13
Cardiovascular Agents: Angina, Hypertension & Heart Failure .....	15
Cardiovascular Agents: Antiarrhythmics .....	20
Cardiovascular Agents: Pulmonary Arterial Hypertension .....	21
Cardiovascular Agents: Lipotropics .....	22
Central Nervous System (CNS) Agents: Alzheimer's Agents .....	24
Central Nervous System (CNS) Agents: Anti-Migraine Agents .....	25
Central Nervous System (CNS) Agents: Anticonvulsants .....	26
Central Nervous System (CNS) Agents: Antidepressants .....	28
Central Nervous System (CNS) Agents: Antipsychotics, Second Generation, Oral .....	30
Central Nervous System (CNS) Agents: Attention Deficit Hyperactivity Disorder Agents .....	32
Central Nervous System (CNS) Agents: Fibromyalgia Agents .....	33
Central Nervous System (CNS) Agents: Medication Assisted Treatment of Opioid Addiction .....	34
Central Nervous System (CNS) Agents: Multiple Sclerosis .....	35
Central Nervous System (CNS) Agents: Neuropathic Pain .....	36
Central Nervous System (CNS) Agents: Parkinson's Agents .....	37
Central Nervous System (CNS) Agents: Restless Legs Syndrome .....	38
Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate .....	39
Central Nervous System (CNS) Agents: Skeletal Muscle Relaxants, Non-Benzodiazepine .....	40
Central Nervous System (CNS) Agents: Smoking Deterrents .....	41
Endocrine Agents: Diabetes Adjunctive Therapy .....	42
Endocrine Agents: Diabetes – Insulin .....	43
Endocrine Agents: Diabetes – Oral Hypoglycemics .....	44
Endocrine Agents: Estrogenic Agents .....	47
Endocrine Agents: Growth Hormone .....	48
Endocrine Agents: Osteoporosis – Bone Ossification Enhancers .....	50
Gastrointestinal Agents: Anti-Emetics .....	51
Gastrointestinal Agents: Irritable Bowel Syndrome / Chronic Constipation Agents .....	52
Gastrointestinal Agents: H. Pylori Packages .....	53
Gastrointestinal Agents: Pancreatic Enzymes .....	54
Gastrointestinal Agents: Proton Pump Inhibitors .....	55
Gastrointestinal Agents: Ulcerative Colitis Agents .....	56
Genitourinary Agents: Benign Prostatic Hyperplasia .....	57
Genitourinary Agents: Electrolyte Depletter Agents .....	58
Genitourinary Agents: Urinary Antispasmodics .....	59
Immunomodulator Agents for Systemic Inflammatory Disease .....	60
Infectious Disease Agents: Antibiotics – Cephalosporins .....	61
Infectious Disease Agents: Antibiotics – Macrolides .....	63
Infectious Disease Agents: Antibiotics – Quinolones .....	64
Infectious Disease Agents: Antifungals for Onychomycosis & Systemic Infections .....	65
Infectious Disease Agents: Antivirals – Hepatitis C Agents .....	66
Infectious Disease Agents: Antivirals – Herpes .....	67
Infectious Disease Agents: Antivirals – HIV .....	68
Ophthalmic Agents: Antibiotic and Antibiotic-Steroid Combination Drops and Ointments .....	70
Ophthalmic Agents: Antihistamines & Mast Cell Stabilizers .....	72
Ophthalmic Agents: Glaucoma Agents .....	73
Ophthalmic Agents: NSAIDs .....	75
Otic Agents: Antibacterial and Antibacterial/Steroid Combinations .....	76
Respiratory Agents: Antihistamines – Second Generation .....	77
Respiratory Agents: Beta-Adrenergic Agonists – Inhaled, Short Acting .....	78

Respiratory Agents: Beta-Adrenergic Agonists – Inhaled, Long Acting .....	79
Respiratory Agents: Chronic Obstructive Pulmonary Disease.....	80
Respiratory Agents: Epinephrine Auto-Injectors .....	81
Respiratory Agents: Glucocorticoid Agents – Inhaled .....	82
Respiratory Agents: Leukotriene Receptor Modifiers and Inhibitors .....	83
Respiratory Agents: Nasal Preparations.....	84
Topical Agents: Acne Preparations.....	85
Topical Agents: Androgens.....	87
Topical Agents: Anti-Fungals .....	88
Topical Agents: Anti-Parasitics.....	89
Topical Agents: Corticosteroids.....	90
Topical Agents: Immunomodulators.....	92

## Analgesic Agents: Gastroprotective NSAIDs

**LENGTH OF AUTHORIZATIONS:** 1 year, except as specified in items (2) and (3) under Additional Information

### **ADDITIONAL INFORMATION**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?  
Acceptable reasons include:

- Allergy to non-gastroprotective NSAIDs
  - Contraindication to or drug-to-drug interaction with medications not requiring prior approval. Acceptable contraindications include:
    - Concurrent or history of a GI event (perforation, ulcer, bleed)
    - Other risks for treatment with non-selective NSAIDs:
      - Coagulation disorders (i.e. hemophilia, chronic liver disease), erosive esophagitis
      - Documented NSAID-induced ulcer
      - Peptic ulcer disease (PUD)
      - Patient on warfarin or heparin
      - Patient on oral corticosteroids
      - Patient on methotrexate
  - History of unacceptable/toxic side effects to medications not requiring prior approval including non-gastroprotective NSAIDs
1. Preferred gastroprotective NSAIDs may be approved if there have been therapeutic failures to no less than a one-month trial of at least two non-gastroprotective NSAID medications.
  2. Preferred gastroprotective NSAIDs may be approved for patients who are undergoing surgical or other medical procedures that may predispose them to potential bleeding complications. Authorization will be for a 2-month period.
  3. Preferred gastroprotective NSAIDs may be approved for patients who are being treated for H. pylori. Authorization will be for a 30-day period.

### **CRITERIA FOR SYSTEMATIC PA OF PREFERRED AGENTS**

1. Patient age equal to or over 60 years; or
2. Patient has claims history of warfarin, heparin, or heparin-related agents in past 120 days; or
3. Patient has claims history of oral corticosteroid in past 120 days; or
4. Patient has claims history of methotrexate in past 120 days; or
5. Patient has claims history of aspirin in past 120 days; or
6. If there have been therapeutic failures to no less than a one-month trial of at least two non-gastroprotective NSAID medications from the same prescriber.

### **ANALGESIC AGENTS: GASTROPROTECTIVE NSAIDS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CELEBREX <sup>®</sup> (celecoxib) (no PA required for age 60 or older)	CELEBREX <sup>®</sup> (celecoxib) (PA required for under age 60) DICLOFENAC/MISOPROSTOL (generic of Arthrotec <sup>®</sup> ) DUEXIS <sup>®</sup> (ibuprofen/famotidine) VIMOVO <sup>®</sup> (naproxen/esomeprazole)

## Analgesic Agents: Gout

**LENGTH OF AUTHORIZATIONS:** 1 year

Is there any reason the patient cannot be changed to an agent not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
- History of unacceptable/toxic side effects to medications not requiring prior approval

**ADDITIONAL INFORMATION**

The requested medication may be approved if the following is true:

- Agents to reduce hyperuricemia will be approved after adequate trial of allopurinol, or intolerance/contraindication to allopurinol.
- Analgesic agents will be approved if any one of the following is true:
  - Diagnosis of Familial Mediterranean Fever (FMF) (6 month approval); OR
  - Trial of one of the following:
    - NSAID (i.e., indomethacin, naproxen, ibuprofen, sulindac, ketoprofen)
    - Oral corticosteroid

**ANALGESIC AGENTS: GOUT – Agents to Reduce Hyperuricemia**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ALLOPURINOL (generic of Zyloprim®) PROBENECID (generic for Benemid®) PROBENECID-COLCHICINE	ULORIC® (febuxostat)

**ANALGESIC AGENTS: GOUT – Analgesic Agents**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	COLCRYS® * (colchicine)

\* Colcris® (colchicine) quantity limit 6 tabs/claim for acute gout, 60 tabs/month for chronic gout after trial on xanthine oxidase inhibitor, 120 tabs/month for FMF

## Analgesic Agents: Opioids

**LENGTH OF AUTHORIZATIONS:** 6 months

**STEP THERAPY:** Long-acting drugs

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one week of at least one preferred generic
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one week each of at least two preferred generics or brands

**STEP THERAPY:** Short-acting drugs

- 1) Short-acting, single entity, CII tablets/capsules require previous utilization of at least one combination product or tramadol, for no less than one week
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one week each of at least two preferred agents

**OTHER APPROVAL CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?  
Acceptable reasons include:

- Allergy to at least two unrelated medications not requiring prior approval
- Contraindication to or drug-to-drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval
- Patient must have failed the generic product (if covered by the state) before brand is authorized, in addition to the above.

**ADDITIONAL CRITERIA FOR TRANSMUCOSAL FENTANYL:**

- Diagnosis of cancer pain; and
- Prescription is from oncologist or pain specialist; and
- Concurrently taking a long-acting opioid at therapeutic dose (any of the following for  $\geq 1$  week without adequate pain relief):
  - $\geq 60$  mg oral morphine/day, or
  - $\geq 25$  mcg/hr transdermal fentanyl, or
  - $\geq 30$  mg oral oxycodone/day, or
  - $\geq 8$  mg oral hydromorphone/day, or
  - $\geq 25$  mg oral oxymorphone/day, or
  - Equianalgesic dose of another opioid; and
- Dose is  $\leq 4$  units per day

**ADDITIONAL CRITERIA FOR TRANSDERMAL BUPRENORPHINE (BUTRANS®):**

Butrans® may be approved under the criteria for non-preferred short-acting products or non-preferred long-acting products.

**ANALGESIC AGENTS: OPIOIDS – Long-Acting Oral**

<b>NO PA REQUIRED "PREFERRED GENERIC"</b>	<b>STEP THERAPY REQUIRED "PREFERRED BRAND"</b>	<b>PA REQUIRED</b>
<b>Extended Release Morphine Products</b>		
MORPHINE SULFATE ER tablet (generic of MS Contin <sup>®</sup> )	KADIAN <sup>®</sup> (morphine)	AVINZA <sup>®</sup> (morphine) MORPHINE SULFATE ER capsule (generic of Kadian <sup>®</sup> )
<b>Extended Release Oxycodone Products</b>		
		OXYCONTIN <sup>®</sup> (oxycodone)
<b>Extended Release Tramadol Products</b>		
		CONZIP <sup>®</sup> (tramadol) TRAMADOL ER (generic of Ryzolt ER <sup>®</sup> , Ultram ER <sup>®</sup> )
<b>Extended Release Oxymorphone Products</b>		
		OXYMORPHONE HCL ER tablets (generic of Opana <sup>®</sup> ER)
<b>Extended Release Hydromorphone Products</b>		
		EXALGO <sup>®</sup> ER (hydromorphone)
<b>Extended Release Tapentadol Products</b>		
	NUCYNTA ER <sup>®</sup>	

**ANALGESIC AGENTS: OPIOIDS – Long-Acting Transdermal**

<b>NO PA REQUIRED "PREFERRED GENERIC"</b>	<b>STEP THERAPY REQUIRED "PREFERRED BRAND"</b>	<b>PA REQUIRED</b>
FENTANYL PATCH (generic of Duragesic <sup>®</sup> )		BUTRANS <sup>®</sup> PATCH (buprenorphine)

**ANALGESIC AGENTS: OPIOIDS – Short-Acting Oral Single-Entity CII \***

\* Note: Step therapy required for all Short-Acting Oral Single-Entity CII products; patient must have prior therapy with combination products or tramadol

<b>STEP THERAPY REQUIRED “PREFERRED”</b>	<b>PA REQUIRED</b>
<b>Codeine Products</b>	
CODEINE SULFATE TABLETS	
<b>Hydromorphone Products</b>	
HYDROMORPHONE HCL TABLETS (generic of Dilaudid®)	
<b>Levorphanol Products</b>	
	LEVORPHANOL TABLETS (generic of Levo-Dromoran)
<b>Meperidine Products</b>	
MEPERIDINE TABLETS (generic of Demerol®)	
<b>Methadone Products</b>	
METHADONE TABLETS (generic of Dolophine®)	
<b>Morphine Products</b>	
MORPHINE SULFATE: immediate-release tablets (generic of MSIR®)	
<b>Oxycodone Products</b>	
ROXICODONE® tablets OXYCODONE HCL capsules, tablets (generic of M-Oxy®, OxyIR®)	OXECTA® (oxycodone)
<b>Oxymorphone Products</b>	
	OXYMORPHONE HCL tablets (generic of Opana®)
<b>Tapentadol Products</b>	
NUCYNTA® (tapentadol)	

### ANALGESIC AGENTS: OPIOIDS – Short-Acting Combination

NO PA REQUIRED “PREFERRED”	PA REQUIRED
<b>Codeine Combinations</b>	
ACETAMINOPHEN w/CODEINE TABLETS (generic of Tylenol® #2, #3, #4)	
<b>Dihydrocodeine Combinations</b>	
	DIHYDROCODEINE/ACETAMINOPHEN/ CAFFEINE (generic of Zerlor®) SYNALGOS-DC® (dihydrocodeine/aspirin/caffeine) TREZIX® (acetaminophen/caffeine/dihydrocodeine)
<b>Hydrocodone Combinations</b>	
HYDROCODONE/ACETAMINOPHEN tablets (generic of Anexsia, Lorcet, Lortab, Maxidone, Norco, Vicodin)	HYDROCODONE/ IBUPROFEN (generic of Vicoprofen®) IBUDONE® (hydrocodone/ibuprofen) HYDROCODONE/ACETAMINOPHEN (generic of Xodol®) ZYDONE® (hydrocodone/ acetaminophen)
<b>Oxycodone Combinations</b>	
OXYCODONE W/ ACETAMINOPHEN tablets (generic of Percocet®) OXYCODONE W/ ACETAMINOPHEN capsules (generic of Tylox®) OXYCODONE W/ ASPIRIN tablets 4.5mg/325mg (generic of Percodan®)	MAGNACET® (oxycodone/ acetaminophen) OXYCODONE W/ IBUPROFEN (generic of Combunox®) PRIMLEV® (oxycodone/ acetaminophen)
<b>Pentazocine Combinations</b>	
<i>Not advocated for use</i>	PENTAZOCINE/NALOXONE (generic of Talwin NX®) PENTAZOCINE HCL/ ACETAMINOPHEN (generic of Talacen®)
<b>Tramadol Combinations</b>	
	TRAMADOL/ACETAMINOPHEN (generic of Ultracet®)
<b>Carisoprodol Combinations</b>	
	CARISOPRODOL/ASPIRIN/CODEINE (generic of Soma Compound w/Codeine®)

### ANALGESIC AGENTS: CENTRAL, WITH OPIOID ACTIVITY

NO PA REQUIRED “PREFERRED”	PA REQUIRED
TRAMADOL (generic of Ultram®)	RYBIX® ODT (tramadol)

**ANALGESIC AGENTS: OPIOIDS –Liquids Immediate-Release (Single Entity)**

<b>NO PA REQUIRED “PREFERRED”</b>	<b>PA REQUIRED</b>
HYDROMORPHONE 1mg/ml liquid (generic of Dilaudid-5 <sup>®</sup> ) MEPERIDINE HCL SYRUP 50 mg/5ml (generic of Demerol Oral Syrup <sup>®</sup> ) METHADONE HCL oral concentrate 10mg/ml METHADONE HCL SOLN 5mg/5ml, 10mg/5ml METHADONE INTENSOL <sup>®</sup> 10mg/ml MORPHINE SULFATE solution: 10 mg/5ml, 20mg/5ml, 20mg/ml (generic of MSIR Soln <sup>®</sup> , Roxanol Soln <sup>®</sup> ) OXYCODONE oral solution 5mg/5ml, concentrate 20mg/1ml (generic of Oxydose <sup>®</sup> , Roxicodone Intensol <sup>®</sup> )	

**ANALGESIC AGENTS: OPIOIDS – Liquids and Oral Syrup Immediate-Release (Combination)**

<b>NO PA REQUIRED “PREFERRED”</b>	<b>PA REQUIRED</b>
ACETAMINOPHEN w/CODEINE ORAL SOLN 120mg-12mg/5ml (generic of Tylenol w/Codeine Elixir <sup>®</sup> ) HYDROCODONE BITARTRATE w/ ACETAMINOPHEN ELIXIR 2.5mg-167mg/5ml (generic of Lortab Elixir <sup>®</sup> ) ROXICET ORAL SOLN <sup>®</sup> (5mg Oxycodone-325mg APAP/5ml)	CAPITAL w/CODEINE <sup>®</sup> suspension 12mg codeine-120mg APAP/5ml HYCET <sup>®</sup> (hydrocodone/ acetaminophen) HYDROCODONE/ACETAMINOPHEN ORAL SOLUTION 10mg-325mg/15ml (generic of Zamicet <sup>®</sup> ) ZOLVIT <sup>®</sup> (hydrocodone/acetaminophen)

**ANALGESIC AGENTS: OPIOIDS – Nasal Inhalers**

<b>NO PA REQUIRED “PREFERRED”</b>	<b>PA REQUIRED</b>
BUTORPHANOL TARTRATE NS (generic of Stadol NS <sup>®</sup> )	

**ANALGESIC AGENTS: OPIOIDS – Transmucosal System \***

<b>NO PA REQUIRED “PREFERRED”</b>	<b>PA REQUIRED</b>
	ABSTRAL <sup>®</sup> (fentanyl) FENTANYL CITRATE (generic of Actiq <sup>®</sup> ) FENTORA <sup>®</sup> (fentanyl) ONSOLIS <sup>®</sup> (fentanyl) SUBSYS <sup>®</sup> (fentanyl)

\* Note: Clinical criteria must be met for transmucosal systems

## Blood Formation, Coagulation, and Thrombosis Agents: Hematopoietic Agents

**LENGTH OF AUTHORIZATIONS:**      Dependent on diagnosis

**ALL PRODUCTS IN THIS CLASS REQUIRE CLINICAL PRIOR AUTHORIZATION:**

Approval of epoetin alfa or darbepoetin:

Diagnosis	Hemoglobin Level	Approval Length
Anemia due to chronic renal failure, patient on dialysis	<=11	12 months
Anemia due to chronic renal failure, patient not on dialysis	<=10	12 months
Chemotherapy-induced anemia	<=10	3 months
Anemia in myelodysplastic syndrome	<=11	6 months

Approval of epoetin alfa only (not darbepoetin):

Diagnosis	Hemoglobin Level	Approval Length
Autologous blood donation, patient will require blood transfusions	>10, <=13	1 month
Anemia of prematurity, age <=6 months	N/A	6 weeks
Anemia associated with chronic inflammatory disorders (e.g., rheumatoid arthritis)	<=11	6 months
Anemia associated with ribavirin combination therapy in hepatitis C-infected patient	<=11	6 months
Anemia in zidovudine-treated HIV-infected patients	<=11	6 months

**PDL CRITERIA:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. Has the patient failed therapeutic trials of two weeks with preferred medications?

**BLOOD AGENTS: HEMATOPOIETIC AGENTS**

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED "NON-PREFERRED"
ARANESP® (darbepoetin alfa) PROCRIT® (epoetin alfa)	EPOGEN® (epoetin alfa)

## Blood Formation, Coagulation, and Thrombosis Agents: Heparin-Related Preparations

**LENGTH OF AUTHORIZATIONS:**      Varies based on criteria below

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. Has the patient failed therapeutic trials of two weeks with medications not requiring prior approval?

**DURATION OF THERAPY LIMIT:**      35 days

Guidelines from the American College of Chest Physicians limit duration of therapy in the outpatient setting for most indications to less than five weeks. Patients should be transitioned to oral warfarin as soon as possible.

Is there any reason the patient cannot be changed to oral warfarin? Acceptable reasons include:

- patients with cancer (approved up to 6 months),
- pregnant women (approved up to 40 weeks), or
- patients unable to take warfarin (approved up to 6 months).

### **BLOOD AGENTS: HEPARIN-RELATED PREPARATIONS**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
FRAGMIN <sup>®</sup> (dalteparin) LOVENOX <sup>®</sup> (enoxaparin)	FONDAPARINUX (generic of Arixtra <sup>®</sup> ) ENOXAPARIN (generic of Lovenox <sup>®</sup> )

## Blood Formation, Coagulation, and Thrombosis Agents: Oral Anticoagulants

**LENGTH OF AUTHORIZATIONS:** 1 year

**INDICATIONS:**

		Apixaban	Clopidogrel	Dabigatran	Prasugrel	Rivaroxaban	Ticagrelor	Warfarin
	Prophylaxis of DVT in patients undergoing total hip or knee replacement					✓ (10mg)		
Reduction of atherosclerotic events:	After cardiac valve replacement							✓
	In established peripheral arterial disease		✓					
	In non-STEMI ACS		✓		✓		✓	✓
	In non-valvular atrial fibrillation	✓		✓		✓ (15 & 20mg)		✓
	In recent MI or stroke		✓					✓
	In STEMI ACS		✓		✓		✓	✓
	Venous thrombosis, pulmonary embolism					✓ (15 & 20mg)		✓

DVT: deep vein thrombosis; STEMI: ST-elevated myocardial infarction; ACS: acute coronary syndrome; MI: myocardial infarction

**APPROVAL CRITERIA:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. Has the patient failed a therapeutic trial of two weeks with one medication not requiring prior approval?

**BLOOD AGENTS: ORAL ANTICOAGULANTS**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
BRILINTA <sup>®</sup> (ticagrelor) CLOPIDOGREL (generic of Plavix <sup>®</sup> ) EFFIENT <sup>®</sup> (prasugrel) WARFARIN (generic of Coumadin <sup>®</sup> ) XARELTO <sup>®</sup> (rivaroxaban) *	ELIQUIS <sup>®</sup> (apixaban) PRADAXA <sup>®</sup> (dabigatran)

\* Note: Duration limit of 35 days applies to Xarelto 10mg tablets, see Heparin-Related Preparations for details

## Cardiovascular Agents: Angina, Hypertension & Heart Failure

**LENGTH OF AUTHORIZATIONS:** 1 year

### **ANGIOTENSIN II RECEPTOR ANTAGONIST (ARB) AND ARB COMBINATION STEP THERAPY:**

1. For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one month of at least one preferred generic
2. For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands
3. For ARB/calcium channel blocker combinations, the preferred generic trial may be a calcium channel blocker or ARB

### **CHRONIC STABLE ANGINA STEP THERAPY:**

Ranexa® may be approved if there has been a therapeutic failure to no less than a one-month trial of at least two beta blockers and/or calcium channel blockers

### **OTHER APPROVAL CRITERIA:**

1. Is there any reason the patient cannot be changed to a preferred medication? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with preferred medications
  - History of unacceptable/toxic side effects to preferred medications
2. The requested medication may be approved if both of the following are true:
  - If there has been a therapeutic failure to no less than a one-month trial of at least one medication within the same class not requiring prior approval
  - The requested medication's corresponding generic (if covered by the state) has been attempted and failed or is contraindicated
3. If there is a specific indication for a medication requiring prior approval, for which medications not requiring prior approval are not indicated, then may approve the requested medication. This medication should be reviewed for need at each request for reauthorization.

## CHRONIC STABLE ANGINA

NO PA REQUIRED "PREFERRED"	PA REQUIRED
Generic beta blockers Generic calcium channel blockers	RANEXA <sup>®</sup> (ranolazine)

## ACE INHIBITORS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
BENAZEPRIL (generic of Lotensin <sup>®</sup> ) CAPTOPRIL (generic of Capoten <sup>®</sup> ) ENALAPRIL (generic of Vasotec <sup>®</sup> ) FOSINOPRIL (generic of Monopril <sup>®</sup> ) LISINOPRIL (generic of Zestril <sup>®</sup> , Prinivil <sup>®</sup> ) MOEXIPRIL (generic of Univasc <sup>®</sup> ) PERINDOPRIL ERBUMINE (generic of Aceon <sup>®</sup> ) QUINAPRIL (generic of Accupril <sup>®</sup> ) RAMIPRIL (generic of Altace <sup>®</sup> ) TRANDOLAPRIL (generic of Mavik <sup>®</sup> )	

## ACE INHIBITORS/CCB COMBINATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
AMLODIPINE/BENAZEPRIL (generic of Lotrel <sup>®</sup> ) TARKA <sup>®</sup> (verapamil/trandolapril)	

## ACE INHIBITORS/DIURETIC COMBINATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
BENAZEPRIL/HCTZ (generic of Lotensin HCT <sup>®</sup> ) CAPTOPRIL/HCTZ (generic of Capozide <sup>®</sup> ) ENALAPRIL/HCTZ (generic of Vaseretic <sup>®</sup> ) FOSINOPRIL/HCTZ (generic of Monopril HCT <sup>®</sup> ) LISINOPRIL/HCTZ (generic of Zestoretic <sup>®</sup> , Prinzide <sup>®</sup> ) MOEXIPRIL/HCTZ (generic of Uniretic <sup>®</sup> ) QUINAPRIL/HCTZ (generic of Accuretic <sup>®</sup> )	

## ALPHA-BETA BLOCKERS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CARVEDILOL (generic of Coreg <sup>®</sup> ) LABETALOL (generic of Trandate <sup>®</sup> )	COREG CR <sup>™</sup> (carvedilol)

## ANGIOTENSIN II RECEPTOR ANTAGONISTS

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
IRBESARTAN (generic of Avapro <sup>®</sup> ) LOSARTAN (generic of Cozaar <sup>®</sup> )	BENICAR <sup>®</sup> (olmesartan) MICARDIS <sup>®</sup> (telmisartan) DIOVAN <sup>®</sup> (valsartan)	CANDESARTAN (generic of Atacand <sup>®</sup> ) EDARBI <sup>®</sup> (azilsartan) EPROSARTAN (generic of Teveten <sup>®</sup> )

### ANGIOTENSIN II RECEPTOR ANTAGONISTS/ DIURETIC COMBINATION

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
IRBESARTAN-HCTZ (generic of Avalide <sup>®</sup> ) LOSARTAN-HCTZ (generic of Hyzaar <sup>®</sup> ) VALSARTAN/HCTZ (generic of Diovan HCT <sup>®</sup> )	BENICAR HCT <sup>®</sup> (olmesartan/hctz) MICARDIS HCT <sup>®</sup> (telmisartan/hctz)	CANDESARTAN/HCTZ (generic of Atacand HCT <sup>®</sup> ) EPROSARTAN/HCTZ (generic of Teveten HCT <sup>®</sup> ) EDARBYCLOR <sup>™</sup> (azilsartan/chlorthalidone)

### ANGIOTENSIN II RECEPTOR ANTAGONISTS/ CALCIUM CHANNEL BLOCKER COMBINATION

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
	AZOR <sup>®</sup> (amlodipine/olmesartan) EXFORGE <sup>®</sup> (amlodipine/valsartan)	TWYNSTA <sup>®</sup> (amlodipine/telmisartan)

### ANGIOTENSIN II RECEPTOR ANTAGONISTS/ CALCIUM CHANNEL BLOCKER/DIURETIC COMBINATION

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
	EXFORGE HCT <sup>®</sup> (amlodipine/valsartan/hctz) TRIBENZOR <sup>®</sup> (olmesartan/amlodipine/hctz)	

### BETA-BLOCKERS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ACEBUTOLOL (generic of Sectral <sup>®</sup> ) ATENOLOL (generic of Tenormin <sup>®</sup> ) BETAXOLOL (generic of Kerlone <sup>®</sup> ) BISOPROLOL FUMARATE (generic of Zebeta <sup>®</sup> ) METOPROLOL SUCCINATE (generic of Toprol XL <sup>®</sup> ) METOPROLOL TARTRATE (generic of Lopressor <sup>®</sup> ) NADOLOL (generic of Corgard <sup>®</sup> ) PINDOLOL (generic of Visken <sup>®</sup> ) PROPRANOLOL (generic of Inderal <sup>®</sup> ) PROPRANOLOL ER (generic of Inderal LA <sup>®</sup> ) SOTALOL (generic of Betapace <sup>®</sup> ) SOTALOL AF (generic of Betapace AF <sup>®</sup> ) TIMOLOL (generic of Blocadren <sup>®</sup> )	BYSTOLIC <sup>®</sup> (nebivolol) INNOPRAN XL <sup>®</sup> (propranolol) LEVATOL <sup>®</sup> (penbutolol)

### BETA-BLOCKERS/DIURETIC COMBINATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ATENOLOL/CHLORTHALIDONE (generic of Tenoretic <sup>®</sup> ) BISOPROLOL/HCTZ (generic of Ziac <sup>®</sup> ) DUTOPROL <sup>®</sup> (metoprolol succinate/HCTZ) METOPROLOL/HCTZ (generic of Lopressor HCT <sup>®</sup> ) NADOLOL/BENDROFLUMETHIAZIDE (generic of Corzide <sup>®</sup> ) PROPRANOLOL/HCTZ (generic of Inderide <sup>®</sup> )	

### CALCIUM CHANNEL BLOCKERS- DIHYDROPYRIDINE

NO PA REQUIRED "PREFERRED"	PA REQUIRED
AMLODIPINE (generic of Norvasc <sup>®</sup> ) FELODIPINE (generic of Plendil <sup>®</sup> ) NICARDIPINE (generic of Cardene <sup>®</sup> ) NIFEDIPINE ER (generic of Procardia XL <sup>®</sup> , Adalat CC <sup>®</sup> ) NIFEDIPINE IMMEDIATE RELEASE (generic of Procardia <sup>®</sup> )	CARDENE SR <sup>®</sup> (nicardipine) ISRADIPINE (generic of Dynacirc <sup>®</sup> ) NIMODIPINE (generic of Nimotop <sup>®</sup> )* NISOLDIPINE (generic of Sular <sup>®</sup> )

\* Note: Clinical criteria required for nimodipine, only approvable for 21 days after subarachnoid hemorrhage.

### CALCIUM CHANNEL BLOCKERS- NON-DIHYDROPYRIDINE

NO PA REQUIRED "PREFERRED"	PA REQUIRED
DILTIAZEM (generic of Cardizem <sup>®</sup> ) DILTIAZEM ER (generic of Cardizem CD <sup>®</sup> q24h, Tiazac <sup>®</sup> ) DILTIAZEM SR (generic of Cardizem SR <sup>®</sup> q12h) VERAPAMIL (Generic of Calan <sup>®</sup> ) VERAPAMIL SR/ER (Generic of Calan SR <sup>®</sup> , Isoptin SR <sup>®</sup> , Verelan <sup>®</sup> )	DILTIAZEM 24H ER tablet (generic of Cardizem LA <sup>®</sup> ) VERAPAMIL ER PM (generic of Verelan PM <sup>®</sup> )

### DIRECT RENIN INHIBITORS\*

STEP THERAPY REQUIRED "PREFERRED"	PA REQUIRED
TEKTURNA <sup>®</sup> (aliskiren)	

\* Note: Step therapy required for direct renin inhibitors – patient must have a claim for an alternative anti-hypertensive agent within the last 120 days.

### DIRECT RENIN INHIBITOR/DIURETIC Combination\*

STEP THERAPY REQUIRED "PREFERRED"	PA REQUIRED
TEKTURNA HCT <sup>®</sup> (aliskiren/HCTZ)	

\* Note: Step therapy required for direct renin inhibitors – patient must have a claim for an alternative anti-hypertensive agent within the last 120 days.

### DIRECT RENIN INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATION\*

STEP THERAPY REQUIRED "PREFERRED"	PA REQUIRED
TEKAMLO <sup>®</sup> (aliskiren/amlodipine)	

\* Note: Step therapy required for direct renin inhibitors – patient must have a claim for an alternative anti-hypertensive agent within the last 120 days.

**DIRECT RENIN INHIBITOR/CALCIUM CHANNEL BLOCKER/DIURETIC  
Combination\***

<b>STEP THERAPY REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
AMTURNIDE <sup>®</sup> (aliskiren/amlodipine/HCTZ)	

\* Note: Step therapy required for direct renin inhibitors – patient must have a claim for an alternative anti-hypertensive agent within the last 120 days.

## Cardiovascular Agents: Antiarrhythmics

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. Has the patient failed a therapeutic trial of one month with one medication not requiring prior approval?

### CARDIOVASCULAR AGENTS: ANTIARRHYTHMICS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
AMIODARONE (generic of Cordarone <sup>®</sup> ) 200mg	AMIODARONE 100mg, 400mg
DISOPYRAMIDE PHOSPHATE IR (generic of Norpace <sup>®</sup> )	MULTAQ <sup>®</sup> (dronedarone)
DISOPYRAMIDE PHOSPHATE ER (generic of Norpace <sup>®</sup> CR)	
FLECAINIDE (generic of Tambacor <sup>®</sup> )	
MEXILITINE	
NORPACE CR <sup>®</sup> (disopyramide)	
PROPAFENONE (generic of Rythmol <sup>®</sup> )	
PROPAFENONE ER (generic of Rythmol SR <sup>®</sup> )	
QUINIDINE GLUCONATE ER	
QUINIDINE SULFATE	
QUINIDINE SULFATE ER	
RYTHMOL SR <sup>®</sup> (propafenone)	
TIKOSYN <sup>®</sup> (dofetilide)	

## Cardiovascular Agents: Pulmonary Arterial Hypertension

**LENGTH OF AUTHORIZATIONS:** 1 year

All products in this class require clinical prior authorization: Diagnosis of pulmonary arterial hypertension

**GRANDFATHERING:**

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug through the automated PA system. Patients who have taken the drug in the previous 120 days, but do not have claims history (new to Medicaid, samples, etc.), will be approved for PA after prescriber contact.

1. Patients diagnosed as World Health Organization Group 3 or more severe may be approved for inhalation or intravenous agents
2. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
3. Has the patient failed a therapeutic trial of at least one month with at least one medication not requiring prior approval?

**CARDIOVASCULAR AGENTS: PULMONARY ARTERIAL HYPERTENSION ORAL \***

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED
ADCIRCA <sup>®</sup> (tadalafil) LETAIRIS <sup>®</sup> (ambrisentan) SILDENAFIL (generic of Revatio <sup>®</sup> ) TRACLEER <sup>®</sup> (bosentan)	

\*Patients on current regimens will be grandfathered.

**CARDIOVASCULAR AGENTS: PULMONARY ARTERIAL HYPERTENSION INHALATION \***

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED
	TYVASO <sup>®</sup> (treprostinil) VENTAVIS <sup>®</sup> (iloprost)

\*Patients on current regimens will be grandfathered.

**CARDIOVASCULAR AGENTS: PULMONARY ARTERIAL HYPERTENSION INTRAVENOUS \***

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED
	EPOPROSTENOL (generic of Flolan <sup>®</sup> ) REMODULIN <sup>®</sup> (treprostinil) VELETRI <sup>®</sup> (epoprostenol)

\*Patients on current regimens will be grandfathered.



### CARDIOVASCULAR AGENTS: LIPOTROPICS - STATINS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ATORVASTATIN (generic of Lipitor®) LOVASTATIN (generic of Mevacor®) PRAVASTATIN (generic of Pravachol®) SIMVASTATIN (generic of Zocor®)	ALTOPREV® (lovastatin) CRESTOR® (rosuvastatin) FLUVASTATIN (generic of Lescol®) LESCOL XL® (fluvastatin) LIVALO® (pitavastatin)

### CARDIOVASCULAR AGENTS: LIPOTROPICS – STATIN/NIACIN COMBINATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
SIMCOR® (Simvastatin/Niacin)	ADVICOR® (Lovastatin/Niacin)

### CARDIOVASCULAR AGENTS: LIPOTROPICS - FIBRIC ACID DERIVATIVES

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ANTARA® (fenofibrate) GEMFIBROZIL (generic of Lopid®) TRICOR® (fenofibrate) TRILIPIX® (fenofibric acid)	FENOFIBRATE FENOFIBRIC ACID (generic of Fibracor®) LIPOFEN® (fenofibrate) LOFIBRA® (fenofibrate) TRIGLIDE® (fenofibrate)

### CARDIOVASCULAR AGENTS: LIPOTROPICS - NICOTINIC ACID DERIVATIVES

NO PA REQUIRED PREFERRED	PA REQUIRED
NIACIN NIASPAN® (niacin)	

### CARDIOVASCULAR AGENTS: LIPOTROPICS - OMEGA-3 POLYUNSATURATED FATTY ACIDS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
OTC FISH OIL 340-1000, 360-1200, 435-880, 500-1000	LOVAZA® (omega 3 fatty acids) VASCEPA® (icosapent ethyl)

### CARDIOVASCULAR AGENTS: LIPOTROPICS - SELECTIVE CHOLESTEROL ABSORPTION INHIBITORS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	ZETIA® (ezetimibe)

### CARDIOVASCULAR AGENTS: LIPOTROPICS – STATIN / SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR COMBINATIONS \*

STEP THERAPY REQUIRED "PREFERRED"	PA REQUIRED
	LIPTRUZET® (atorvastatin/ezetimibe) VYTORIN® (simvastatin/ezetimibe)

\* Note: Step therapy required – must have therapeutic trial of two preferred statins.

### CARDIOVASCULAR AGENTS: LIPOTROPIC/HYPERTENSION COMBINATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	AMLODIPINE/ATORVASTATIN (generic of Caduet®)

### CARDIOVASCULAR AGENTS: LIPOTROPIC/DPP-4 COMBINATION \*

STEP THERAPY REQUIRED "PREFERRED"	PA REQUIRED
JUVISYNC® (sitagliptin/simvastatin)	

\* Note: Step therapy required for DPP-4 Inhibitors – patient must have a claim for an alternate oral hypoglycemic or insulin within the previous 120 days.

## Central Nervous System (CNS) Agents: Alzheimer's Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

**GRANDFATHERING:**

Patients who have a claim for a drug requiring step therapy or a non-preferred drug in the previous 120 days will be automatically approved to continue the drug through the automated PA system. Patients who have taken the drug in the previous 120 days, but do not have claims history (new to Medicaid, samples, etc.), will be approved for PA after prescriber contact.

**STEP THERAPY:**

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one month of at least one preferred generic
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands

**OTHER APPROVAL CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug-to-drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**ADDITIONAL CRITERIA FOR RIVASTIGMINE PATCH (EXELON®):**

May be approved first-line for a patient who is unable to swallow.

**CNS AGENTS: ALZHEIMER'S AGENTS**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
DONEPEZIL (generic of Aricept®) DONEPEZIL ODT (generic of Aricept® ODT) GALANTAMINE (generic of Razadyne™) GALANTAMINE ER (generic of Razadyne™ ER) GALANTAMINE 4mg/ml solution (generic of Razadyne™) RIVASTIGMINE capsules (generic of Exelon®)	EXELON® patch (rivastigmine) NAMENDA® (memantine) NAMENDA® 10mg/5ml solution (memantine)	ARICEPT® 23mg EXELON® 2mg/ml solution (rivastigmine) NAMENDA XR®

## Central Nervous System (CNS) Agents: Anti-Migraine Agents

**LENGTH OF AUTHORIZATIONS:** 6 months

**STEP THERAPY:** All anti-migraine agents listed

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than two weeks of at least one preferred generic
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than two weeks each of at least two preferred generics or brands

**OTHER APPROVAL CRITERIA:**

- Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to preferred medications
  - Contraindication to all preferred medications
  - History of unacceptable/toxic side effects to at least two preferred medications

**CLINICAL CONSIDERATIONS:**

Prior Authorization will not be given for prophylaxis unless the patient has exhausted or has contraindications to all other “controller” migraine medications (i.e., beta-blockers, neuroleptics, calcium channel blockers, etc.)

**ADDITIONAL INFORMATION**

In addition to utilizing a preferred agent when applicable, the number of tablets/doses allowed per month is restricted based on the manufacturer’s package insert.

**CNS AGENTS: ANTI-MIGRAINE AGENTS – SEROTONIN 5-HT1 RECEPTOR AGONISTS – “Fast” Onset**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
IMITREX <sup>®</sup> INJECTION (sumatriptan) IMITREX <sup>®</sup> NASAL SPRAY (sumatriptan) RIZATRIPTAN tablets (generic of Maxalt <sup>®</sup> ) RIZATRIPTAN ODT (generic of Maxalt-MLT <sup>®</sup> ) SUMATRIPTAN TABLETS (generic of Imitrex <sup>®</sup> )	AXERT <sup>®</sup> (almotriptan) RELPAX <sup>®</sup> (eletriptan) SUMATRIPTAN injection (generic of Imitrex <sup>®</sup> ) SUMATRIPTAN nasal spray (generic of Imitrex <sup>®</sup> ) SUMAVEL DOSEPRO <sup>®</sup> (sumatriptan) ZOMIG <sup>®</sup> (zolmitriptan) ZOMIG ZMT <sup>®</sup> (zolmitriptan) ZOMIG <sup>®</sup> NASAL SPRAY (zolmitriptan)

**CNS AGENTS: ANTI-MIGRAINE AGENTS – SEROTONIN 5-HT1 RECEPTOR AGONISTS - “Slow” Onset**

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
NARATRIPTAN (generic of Amerge <sup>®</sup> )	FROVA <sup>®</sup> (frovatriptan)	

**CNS AGENTS: ANTI-MIGRAINE AGENTS – SEROTONIN 5-HT1 RECEPTOR AGONIST/NSAID COMBINATION**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
	TREXIMET <sup>®</sup> (sumatriptan/naproxen)

## Central Nervous System (CNS) Agents: Anticonvulsants

**LENGTH OF AUTHORIZATIONS:**      1 year

**GRANDFATHERING:**

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug through the automated PA system. Patients who have taken the drug in the previous 120 days, but do not have claims history (new to Medicaid, samples, etc.), will be approved for PA after prescriber contact.

**OTHER APPROVAL CRITERIA:**

1. Is there any reason the patient cannot be changed to a preferred medication? Acceptable reasons include:
  - Allergy to two preferred medications
  - Contraindication to or drug interaction with two preferred medications
  - History of unacceptable/toxic side effects to two preferred medications
  - The requested medication’s corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.
2. If there has been a therapeutic failure to no less than two preferred products for a one-month trial each.

**ANTICONVULSANTS: CARBAMAZEPINE DERIVATIVES**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CARBAMAZEPINE IR tablet, chewable, oral suspension (generic of Tegretol®) CARBATROL® (carbamazepine 12-hour ER) OXCARBAZEPINE tablet, suspension (generic of Trileptal®) TEGRETOL XR® tablet (carbamazepine 12-hour ER) TRILEPTAL® suspension	CARBAMAZEPINE 12-hour ER capsule, tablet (generic of Carbatrol®, Tegretol XR®) OXTELLAR XR (oxcarbazepine)

**ANTICONVULSANTS: FIRST GENERATION**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CLONAZEPAM tablet (generic of Klonopin®) DIASTAT® rectal gel (diazepam) DIVALPROEX (generic of Depakote®) DIVALPROEX ER (generic of Depakote® ER) ETHOSUXAMIDE (generic of Zarontin®) PHENOBARBITAL PHENYTOIN (generic of Dilantin®) PRIMIDONE (generic of Mysoline®) VALPROIC ACID (generic of Depakene®)	CELONTIN® (methsuximide) CLONAZEPAM ODT (generic of Klonopin® wafer) DIAZEPAM rectal gel (generic of Diastat®) ONFI® (clobazam) PEGANONE® (ethotoin) STAVZOR (valproic acid delayed-release)

## ANTICONVULSANTS: SECOND GENERATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
<p>GABAPENTIN (generic of Neurontin<sup>®</sup>)  LAMOTRIGINE IR tablet, chewable tablet (generic of Lamictal<sup>®</sup>)  LEVETIRACETAM IR tablet, solution (generic of Keppra<sup>®</sup>)  SABRIL<sup>®</sup> powder (no PA for age &lt; 2)  TOPIRAMATE tablet (generic of Topamax<sup>®</sup>)  ZONISAMIDE (generic of Zonegran<sup>®</sup>)</p>	<p>BANZEL<sup>®</sup> (rufinamide)  FELBAMATE (generic of Felbatol<sup>®</sup>)  LAMICTAL<sup>®</sup> ODT  LAMOTRIGINE ER tablet (generic of Lamictal<sup>®</sup> XR)  LEVETIRACETAM ER tablet (generic of Keppra<sup>®</sup> XR)  LYRICA<sup>®</sup> (pregabalin)  POTIGA<sup>®</sup> (ezogabine)  SABRIL<sup>®</sup> powder (PA required for age &gt; 2)  SABRIL<sup>®</sup> tablet (vigabatrin)  TIAGABINE (generic of Gabitril<sup>®</sup>)  TOPIRAMATE sprinkle cap (generic of Topamax<sup>®</sup> sprinkle cap)  TROKENDI XR<sup>®</sup> (topiramate)  VIMPAT<sup>®</sup> (lacosamide)</p>

## Central Nervous System (CNS) Agents: Antidepressants

### **GRANDFATHERING:**

Patients who have a claim for a non-preferred drug, or drug requiring step therapy, in the previous 120 days will be automatically approved to continue the drug through the automated PA system. Patients who have taken the drug in the previous 120 days, but do not have claims history (new to Medicaid, samples, etc.), will be approved for PA after prescriber contact.

### **PSYCHIATRIST EXEMPTION:**

Physicians who are registered with Ohio Medicaid as having a specialty in psychiatry are exempt from prior authorization of any non-preferred antidepressant, or step therapy of any preferred brand, in the standard tablet/capsule dosage forms. Other dosage forms may still require prior authorization by a psychiatrist. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the psychiatrist.

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY:** All antidepressants listed

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one month of at least one preferred generic
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands

### **OTHER APPROVAL CRITERIA:**

Is there any reason the patient cannot be changed to a preferred medication? Acceptable reasons include:

- Allergy to preferred medications
- Contraindication to or drug interaction with preferred medications
- History of unacceptable/toxic side effects to preferred medications
- For orally disintegrating tablet dosage forms, the patient is unable or unwilling to swallow the standard tablet/capsule dosage form.
- The requested medication's corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.

### **ANTIDEPRESSANTS: SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI)\***

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
CITALOPRAM solution (generic of Celexa®)	BRISDELLE® (paroxetine)
CITALOPRAM tablets (generic of Celexa®)	FLUOXETINE ER (generic of Prozac Weekly®)
ESCITALOPRAM (generic of Lexapro®)	FLUVOXAMINE ER (generic of Luvox CR®)
FLUOXETINE HCL capsules, tablets (generic of Prozac®)	PAROXETINE ER (generic of Paxil CR®)
FLUOXETINE HCL solution (generic of Prozac®)	PEXEVA® (paroxetine mesylate)
FLUVOXAMINE MALEATE (generic of Luvox®)	
PAROXETINE HCL (generic of Paxil®)	
SERTRALINE (generic of Zoloft®)	
SERTRALINE oral concentrate (generic of Zoloft®)	

\*Patients on current regimens will be grandfathered.

**ANTIDEPRESSANTS: SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRI)\***

<b>NO PA REQUIRED "PREFERRED GENERIC"</b>	<b>STEP THERAPY REQUIRED "PREFERRED BRAND"</b>	<b>PA REQUIRED</b>
VENLAFAXINE (generic of Effexor <sup>®</sup> ) VENLAFAXINE ER capsule (generic of Effexor XR <sup>®</sup> )	CYMBALTA <sup>®</sup> (duloxetine)	DESVENLAFAXINE ER tablet KHEDEZLA ER <sup>®</sup> PRISTIQ <sup>®</sup> (desvenlafaxine) VENLAFAXINE ER tablet

\*Patients on current regimens will be grandfathered.

**ANTIDEPRESSANTS: NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS (NDRI)\***

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
BUPROPION HCL (generic of Wellbutrin <sup>®</sup> ) BUPROPION SR (generic of Wellbutrin SR <sup>®</sup> ) BUPROPION XL (generic of Wellbutrin XL <sup>®</sup> )	APLENZIN <sup>TM</sup> (bupropion) FORFIVO XL <sup>®</sup> (bupropion)

\*Patients on current regimens will be grandfathered.

**ANTIDEPRESSANTS: ALPHA-2 RECEPTOR ANTAGONISTS\***

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
MIRTAZAPINE (generic of Remeron <sup>®</sup> ) MIRTAZAPINE rapid dissolve (generic of Remeron <sup>®</sup> Sol-Tab)	

\*Patients on current regimens will be grandfathered.

**ANTIDEPRESSANTS: MONOAMINE OXIDASE INHIBITORS (MAOI)\***

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
	EMSAM <sup>®</sup> patches (selegiline) MARPLAN <sup>®</sup> (isocarboxazid) NARDIL <sup>®</sup> (phenelzine) TRANLYCYPROMINE (generic of Parnate <sup>®</sup> )

\*Patients on current regimens will be grandfathered.

**ANTIDEPRESSANTS: SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARI)\***

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
NEFAZODONE TRAZODONE 50mg, 100mg, 150mg	OLEPTRO ER <sup>®</sup> (trazodone) TRAZODONE 300mg

\*Patients on current regimens will be grandfathered.

**ANTIDEPRESSANTS: SSRI - SEROTONIN PARTIAL AGONIST\***

<b>NO PA REQUIRED "PREFERRED GENERIC"</b>	<b>PA REQUIRED</b>
	VIIBRYD <sup>®</sup> (vilazodone)

\*Patients on current regimens will be grandfathered.

## Central Nervous System (CNS) Agents: Antipsychotics, Second Generation, Oral

### **GRANDFATHERING:**

Patients who have a claim for a non-preferred drug, or drug requiring step therapy, in the previous 120 days will be automatically approved to continue the drug through the automated PA system. Patients who have taken the drug in the previous 120 days, but do not have claims history (new to Medicaid, samples, etc.), will be approved for PA after prescriber contact.

### **PSYCHIATRIST EXEMPTION:**

Physicians who are registered with Ohio Health Plans as having a specialty in psychiatry are exempt from prior authorization of any non-preferred second generation antipsychotic, or step therapy of any preferred brand, in the standard tablet/capsule dosage forms. Other dosage forms may still require prior authorization by a psychiatrist. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual identifier for the psychiatrist.

**LENGTH OF AUTHORIZATIONS:** 1 year

### **STEP THERAPY:** all agents listed

1. For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than fourteen days of at least one preferred generic
2. For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than fourteen days each of at least two preferred generics or brands

### **OTHER APPROVAL CRITERIA:**

Is there any reason the patient cannot be changed to a preferred medication? Acceptable reasons include:

- Allergy to preferred medications
- Contraindication to or drug interaction with preferred medications
- History of unacceptable/toxic side effects to preferred medications
- For orally disintegrating tablet dosage forms, the patient is unable or unwilling to swallow the standard tablet/capsule dosage form.
- The requested medication's corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.
- Clozapine or lurasidone (pregnancy category B) may be approved if a patient is pregnant

**ANTIPSYCHOTICS, SECOND GENERATION \***

<b>NO PA REQUIRED "PREFERRED GENERIC"</b>	<b>STEP THERAPY REQUIRED "PREFERRED BRAND"</b>	<b>PA REQUIRED</b>
QUETIAPINE (generic of Seroquel <sup>®</sup> ) RISPERIDONE (generic of Risperdal <sup>®</sup> ) ZIPRASIDONE (generic of Geodon <sup>®</sup> )	ABILIFY <sup>®</sup> (aripiprazole) ABILIFY <sup>®</sup> solution (aripiprazole) SEROQUEL XR <sup>®</sup> (quetiapine)	ABILIFY DISCMELT <sup>®</sup> (aripiprazole) CLOZAPINE (generic of Clozaril <sup>®</sup> ) FANAPT <sup>®</sup> (iloperidone) FAZACLO <sup>®</sup> (clozapine) INVEGA <sup>®</sup> (paliperidone) LATUDA <sup>®</sup> (lurasidone) OLANZAPINE (generic of Zyprexa <sup>®</sup> ) OLANZAPINE ODT (generic of Zyprexa <sup>®</sup> Zydis) SAPHRIS <sup>®</sup> (asenapine)

\*Patients on current regimens will be grandfathered.

**ANTIPSYCHOTICS, SECOND GENERATION and SSRI COMBINATION \***

<b>NO PA REQUIRED "PREFERRED GENERIC"</b>	<b>PA REQUIRED</b>
	FLUOXETINE/OLANZAPINE (generic of Symbyax <sup>®</sup> )

\*Patients on current regimens will be grandfathered.

**ANTIPSYCHOTICS, SECOND GENERATION LONG-ACTING INJECTABLES \* +**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
ABILIFY MAINTENA <sup>®</sup> (aripiprazole) INVEGA SUSTENNA <sup>®</sup> (paliperidone) RISPERDAL CONSTA <sup>®</sup> (risperidone) ZYPREXA RELPREVV <sup>®</sup> (olanzapine)	

\*Patients on current regimens will be grandfathered.

+ Long-Acting Injectable Antipsychotics may be billed by the pharmacy if they are not dispensed directly to the patient. The drug must be released only to the administering provider or administering provider's staff, following all regulations for a Prescription Pick-Up Station as described by the Ohio Board of Pharmacy.

## Central Nervous System (CNS) Agents: Attention Deficit Hyperactivity Disorder Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

Short Acting considered separately from Long Acting products

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to at least two medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to at least two medications not requiring prior approval
  - Daytrana® or Quillivant XR® may be approved if the patient is unable to swallow pills.

### **CNS AGENTS: ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS – Short Acting**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
AMPHETAMINE SALTS (generic of Adderall®)	METHAMPHETAMINE (generic of Desoxyn®)
DEXMETHYLPHENIDATE (generic of Focalin®)	METHYLIN® chewable tablets
DEXTROAMPHETAMINE (generic of Dexedrine®)	PROCENTRA® solution(dextroamphetamine)
DEXTROSTAT® (dextroamphetamine)	ZENZEDI® (dextroamphetamine)
FOCALIN® (dexmethylphenidate)	
METHYLIN® tablets (methylphenidate)	
METHYLIN® solution (methylphenidate)	
METHYLPHENIDATE solution (generic of Methylin®)	
METHYLPHENIDATE tablets (generic of Ritalin®)	

### **CNS AGENTS: ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS – Long Acting**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
ADDERALL XR® (amphetamine/dextroamphetamine)	DAYTRANA® (methylphenidate)
DEXTROAMPHETAMINE SA (generic of Dexedrine® spansule)	DEXTROAMPHETAMINE-AMPHETAMINE (generic of Adderall XR®)
FOCALIN® XR (dexmethylphenidate)	KAPVAY® (clonidine)
INTUNIV® (guanfacine)	METHYLPHENIDATE LA (generic of Metadate® CD, Ritalin® LA)
METADATE® CD (methylphenidate)	QUILLIVANT XR® suspension (methylphenidate)
METADATE® ER (methylphenidate)	
METHYLIN® ER (methylphenidate)	
METHYLPHENIDATE ER (generic of Concerta®)	
METHYLPHENIDATE ER (generic of Ritalin SR®)	
STRATTERA® (atomoxetine)	
VYVANSE™ (lisdexamfetamine)	

## Central Nervous System (CNS) Agents: Fibromyalgia Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

Non-preferred medications will be approved for fibromyalgia after trial of agents from no less than 2 of the following drug classes in the past 90 days (guidelines suggest use of multiple agents concurrently to manage the signs of fibromyalgia):

- Gabapentin
- Pregabalin
- Short- and/or long-acting opioids\*\*
- Skeletal muscle relaxants
- SNRIs
- SSRIs
- Tramadol
- Trazodone
- Tricyclic antidepressants

**\*\* The P&T Committee does not recommend the use of opioids for treatment of fibromyalgia**

### CNS AGENTS: FIBROMYALGIA AGENTS

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED
LYRICA® (pregabalin) *	CYMBALTA® (duloxetine) SAVELLA® (milnacipran)

\* Clinical PA required for Lyrica®, may be approved for diagnosis of fibromyalgia.



# Central Nervous System (CNS) Agents: Multiple Sclerosis

## DISEASE MODIFYING AGENTS

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. The requested medication may be approved if there has been a therapeutic failure to no less than a one-month trial on at least one medication not requiring prior approval.

### **CNS AGENTS: MULTIPLE SCLEROSIS DISEASE MODIFYING AGENTS, INJECTABLE \***

NO PA REQUIRED "PREFERRED"	PA REQUIRED
AVONEX <sup>®</sup> (interferon beta-1a) BETASERON <sup>®</sup> (interferon beta-1b) COPAXONE <sup>®</sup> (glatiramer) REBIF <sup>®</sup> (interferon beta-1a)	EXTAVIA <sup>®</sup> (interferon beta-1b)

\*Patients on current regimens will be grandfathered.

### **CNS AGENTS: MULTIPLE SCLEROSIS DISEASE MODIFYING AGENTS, ORAL \***

NO PA REQUIRED "PREFERRED"	PA REQUIRED
GILENYA <sup>®</sup> (fingolimod)	AUBAGIO <sup>®</sup> (teriflunomide) TECFIDERA <sup>®</sup> (dimethyl fumarate)

\*Patients on current regimens will be grandfathered.

## POTASSIUM CHANNEL BLOCKERS

**LENGTH OF AUTHORIZATIONS:** Initial authorization 180 days,  
Subsequent authorizations 1 year

1. Clinical criteria for initial authorization:
  - Diagnosis of multiple sclerosis; and
  - Prescription written by physician specializing in neurology
2. Criteria for subsequent authorizations
  - Improvement in function

### **CNS AGENTS: MULTIPLE SCLEROSIS POTASSIUM CHANNEL BLOCKERS**

NO PA REQUIRED "PREFERRED"	CLINICAL PA REQUIRED
	AMPYRA <sup>®</sup> (dalfampridine)

## Central Nervous System (CNS) Agents: Neuropathic Pain

**LENGTH OF AUTHORIZATIONS:**      1 year

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### **ADDITIONAL INFORMATION**

The requested medication may be approved if there has been a therapeutic failure to no less than a one-month trial of at least one medication not requiring prior authorization

Lidocaine patch (Lidoderm®) will only be approved for treatment of neuropathic pain (e.g., diabetic peripheral neuropathy, post-herpetic neuralgia).

### **CNS AGENTS: NEUROPATHIC PAIN**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
AMITRIPTYLINE (generic of Elavil®)	CYMBALTA® (duloxetine)
CARBAMAZEPINE (generic of Tegretol®)	GRALISE® (gabapentin)
CLOMIPRAMINE (generic of Anafranil®)	HORIZANT® (gabapentin enacarbil)
DESIPRAMINE (generic of Norpramin®)	LIDODERM® (lidocaine patch)
DOXEPIN (generic of Sinequan®)	LYRICA® (pregabalin)
GABAPENTIN (generic of Neurontin®)	
IMIPRAMINE (generic of Tofranil®)	
NORTRIPTYLINE (generic of Pamelor®)	
OXCARBAZEPINE (generic of Trileptal®)	

## Central Nervous System (CNS) Agents: Parkinson's Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

Is there any reason the patient cannot be changed to a medication not requiring prior approval?  
Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### **ADDITIONAL INFORMATION**

The requested medication may be approved if both of the following are true:

- 1) If there has been a therapeutic failure to no less than a one-month trial of at least one medication not requiring prior approval
- 2) The requested medication's corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.
- 3) Neupro® may be approved if the patient is unable to swallow.

### **PARKINSON'S AGENTS – COMT INHIBITOR**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ENTACAPONE (generic of Comtan®)	TASMAR® (tolcapone)

### **PARKINSON'S AGENTS – DOPAMINE RECEPTOR AGONISTS, NON-ERGOT, INJECTABLE**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	APOKYN® (apomorphine)

### **PARKINSON'S AGENTS – DOPAMINE RECEPTOR AGONISTS, NON-ERGOT, ORAL**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
PRAMIPEXOLE (generic of Mirapex®) ROPINIROLE (generic of Requip®)	MIRAPEX ER® (pramipexole) ROPINIROLE ER (generic of Requip XL®)

### **PARKINSON'S AGENTS – DOPAMINERGIC AGENTS, ORAL**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CARBIDOPA/LEVODOPA (generic of Sinemet®) CARBIDOPA/LEVODOPA CR (generic of Sinemet® CR) SELEGILINE (generic of Eldepryl®)	AZILECT® (rasagiline) CARBIDOPA/LEVODOPA dispersible tablets (generic of Parcopa®) CARBIDOPA/LEVODOPA/ENTACAPONE (generic of Stalevo®) NEUPRO® patch (rotigotine) ZELAPAR® ODT (selegiline)

## Central Nervous System (CNS) Agents: Restless Legs Syndrome

**LENGTH OF AUTHORIZATIONS:** 1 year

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### **ADDITIONAL INFORMATION**

The requested medication may be approved if there has been a therapeutic failure to no less than a one-month trial of at least one medication not requiring prior approval

### **CNS AGENTS: RESTLESS LEGS SYNDROME AGENTS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
PRAMIPEXOLE (generic of Mirapex <sup>®</sup> )	HORIZANT <sup>®</sup> (gabapentin enacarbil)
ROPINIROLE (generic of Requip <sup>®</sup> )	NEUPRO <sup>®</sup> patch (rotigotine)

## Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate

**LENGTH OF AUTHORIZATIONS:**      6 months

**STEP THERAPY:**

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than ten days each of at least two preferred generics
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than ten days each of at least three preferred generics or brands

**OTHER APPROVAL CRITERIA:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If the prescriber indicates the patient has a history of addiction, then may approve a requested non-controlled medication.
3. The P&T Committee does not recommend use of flurazepam (Dalmane<sup>®</sup>) or triazolam (Halcion<sup>®</sup>)

**CNS AGENTS: SEDATIVE-HYPNOTICS, NON-BARBITURATE**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
ESTAZOLAM (generic of Prosom <sup>®</sup> ) TEMAZEPAM 15mg, 30mg (generic of Restoril <sup>®</sup> ) ZALEPLON (generic of Sonata <sup>®</sup> ) ZOLPIDEM (generic of Ambien <sup>®</sup> )	LUNESTA <sup>®</sup> (eszopiclone)	DORAL <sup>®</sup> (quazepam) EDLUAR <sup>®</sup> SL (zolpidem) INTERMEZZO <sup>®</sup> SL (zolpidem) ROZEREM <sup>®</sup> (ramelteon) SILENOR <sup>®</sup> (doxepin) TEMAZEPAM 7.5mg, 22.5mg (generic of Restoril <sup>®</sup> ) ZOLPIDEM ER (generic of Ambien <sup>®</sup> CR) ZOLPIMIST <sup>®</sup> (zolpidem)

## Central Nervous System (CNS) Agents: Skeletal Muscle Relaxants, Non-Benzodiazepine

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If there has been a therapeutic failure to an agent not requiring prior approval, then may approve the requested medication.

### CNS AGENTS: SKELETAL MUSCLE RELAXANTS - ORAL

NO PA REQUIRED "PREFERRED"	PA REQUIRED
BACLOFEN (generic of Lioresal <sup>®</sup> )	CARISOPRODOL (generic of Soma <sup>®</sup> ) *
CHLORZOXAZONE (generic of Parafon Forte <sup>®</sup> )	CARISOPRODOL COMPOUND (generic of Soma Compound <sup>®</sup> ) *
CYCLOBENZAPRINE (generic of Flexeril <sup>®</sup> )	CARISOPRODOL COMPOUND W/CODEINE (generic of Soma Compound w/Codeine <sup>®</sup> ) *
DANTROLENE (generic of Dantrium <sup>®</sup> )	CYCLOBENZAPRINE ER (generic of Amrix <sup>®</sup> )
METHOCARBAMOL (generic of Robaxin <sup>®</sup> )	FEXMID <sup>®</sup> (cyclobenzaprine)
TIZANIDINE tablets (generic of Zanaflex <sup>®</sup> )	LORZONE <sup>®</sup> (chlorzoxazone)
	METAXOLONE (generic of Skelaxin <sup>®</sup> )
	ORPHENADRINE (generic of Norflex <sup>®</sup> )
	ORPHENADRINE COMPOUND (generic of Norgesic <sup>®</sup> )
	ORPHENADRINE COMPOUND FORTE (generic of Norgesic Forte <sup>®</sup> )
	SOMA <sup>®</sup> * (carisoprodol)
	TIZANIDINE capsules (generic of Zanaflex <sup>®</sup> )

\* Note: Clinical criteria must be met for Soma<sup>®</sup>/Carisoprodol products– approvable only if no other muscle relaxant or agent to treat fibromyalgia, or any musculoskeletal condition, would serve the clinical needs of the patient.

## Central Nervous System (CNS) Agents: Smoking Deterrents

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If there has been a therapeutic failure to an agent not requiring prior approval, then may approve the requested medication.

### **CNS AGENTS: SMOKING DETERRENTS – NICOTINE REPLACEMENT**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
COMMIT™ lozenge (nicotine) NICODERM®CQ patch (nicotine) NICORETTE® gum (nicotine) NICOTINE gum (generic of Nicorette®) NICOTINE lozenge (generic of Commit™) NICOTINE patch (generics) NICOTROL® inhaler (nicotine) NICOTROL® nasal spray(nicotine)	

### **CNS AGENTS: SMOKING DETERRENTS – NON-NICOTINE PRODUCTS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
BUPROPION (generic of Zyban®) CHANTIX®(varenicline)	

## Endocrine Agents: Diabetes Adjunctive Therapy

**LENGTH OF AUTHORIZATIONS:** 1 year

All drugs in this class require step therapy: Patient must have a claim for an oral hypoglycemic or insulin in the previous 120 days.

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
  - Condition is difficult to control (i.e. prone to ketoacidosis, hypoglycemia)
2. The requested medication may be approved if there has been a therapeutic failure to at least one medication within the same class not requiring prior authorization.

### **ENDOCRINE AGENTS: DIABETES – AMYLIN ANALOGS**

STEP THERAPY REQUIRED “PREFERRED”	PA REQUIRED
SYMLIN <sup>®</sup> (pramlintide)	

### **ENDOCRINE AGENTS: DIABETES – INCRETIN MIMETICS**

STEP THERAPY REQUIRED “PREFERRED”	PA REQUIRED
BYDUREON <sup>®</sup> (exenatide)	
BYETTA <sup>™</sup> (exenatide)	
VICTOZA <sup>®</sup> (liraglutide)	

## Endocrine Agents: Diabetes – Insulin

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
  - Condition is difficult to control (i.e. prone to ketoacidosis, hypoglycemia)
2. The requested medication may be approved if there has been a therapeutic failure to at least one medication within the same class not requiring prior authorization.

### **ENDOCRINE AGENTS: DIABETES - INSULINS - Rapid and Short Acting\***

NO PA REQUIRED "PREFERRED"	PA REQUIRED
HUMALOG <sup>®</sup> (insulin lispro) HUMULIN R <sup>®</sup> (insulin regular human) HUMULIN R 500-U <sup>®</sup> (insulin regular human) NOVOLIN R <sup>®</sup> (insulin regular human) NOVOLOG <sup>®</sup> (insulin aspart) RELION R <sup>®</sup> (insulin regular human)	APIDRA <sup>®</sup> (insulin glulisine)

\* Patients on current insulin regimens will be grandfathered.

### **ENDOCRINE AGENTS: DIABETES - INSULINS - Intermediate Acting\***

NO PA REQUIRED "PREFERRED"	PA REQUIRED
HUMALOG MIX 50/50, 75/25 <sup>®</sup> (insulin lispro protamine/insulin lispro) HUMULIN 50/50 <sup>®</sup> (insulin NPH/regular) HUMULIN 70/30 <sup>®</sup> (insulin NPH/regular) HUMULIN N <sup>®</sup> (insulin NPH) NOVOLIN 70/30 <sup>®</sup> (insulin NPH/regular) NOVOLIN N <sup>®</sup> (insulin NPH) NOVOLOG MIX 70/30 <sup>®</sup> (insulin aspart protamine/insulin aspart) RELION 70/30 <sup>®</sup> RELION N <sup>®</sup> (insulin NPH)	

\* Patients on current insulin regimens will be grandfathered.

### **ENDOCRINE AGENTS: DIABETES - INSULINS - Long Acting\***

NO PA REQUIRED "PREFERRED"	PA REQUIRED
LANTUS <sup>®</sup> (insulin glargine)	LEVEMIR <sup>®</sup> (insulin detemir)

\* Patients on current insulin regimens will be grandfathered.

## Endocrine Agents: Diabetes – Oral Hypoglycemics

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY:** All oral hypoglycemics

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one month of at least one preferred generic
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands

**OTHER APPROVAL CRITERIA:**

Is there any reason the patient cannot be changed to a medication within the same class not requiring prior approval? Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### DIABETES – ORAL HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
ACARBOSE (generic of Precose <sup>®</sup> )	GLYSET <sup>®</sup> (miglitol)	

### DIABETES – ORAL HYPOGLYCEMICS, BIGUANIDES

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
METFORMIN (generic of Glucophage <sup>®</sup> ) METFORMIN ER (generic of Glucophage XR <sup>®</sup> )		METFORMIN ER (generic of Fortamet <sup>®</sup> ) RIOMET <sup>®</sup> 500mg/5ml (Metformin)

### DIABETES – ORAL HYPOGLYCEMICS, BIGUANIDE/SULFONYLUREA COMBINATION

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
GLIPIZIDE/METFORMIN (generic of Metaglip <sup>®</sup> ) GLYBURIDE/METFORMIN (generic of Glucovance <sup>®</sup> )		

### DIABETES – DIPEPTIDYL PEPTIDASE-4 INHIBITOR

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
	JANUVIA <sup>®</sup> (sitagliptin) TRADJENTA <sup>™</sup> (linagliptin)	NESINA <sup>®</sup> (alogliptin) ONGLYZA <sup>®</sup> (saxagliptin)

**DIABETES – DIPEPTIDYL PEPTIDASE-4 INHIBITOR COMBINATIONS**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
	JANUMET XR™ (sitagliptin/ metformin) JANUMET™ (sitagliptin/metformin) JENTADUETO™ (linagliptin/ metformin)	KAZANO® (alogliptin/ metformin) KOMBIGLYZE XR® (saxagliptin/metformin)

**DIABETES – ORAL HYPOGLYCEMICS, MEGLITINIDES**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
NATEGLINIDE (generic of Starlix®)		REPAGLINIDE (generic of Prandin®)

**DIABETES – ORAL HYPOGLYCEMICS, MEGLITINIDE/BIGUANIDE  
COMBINATION**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
		PRANDIMET® (repaglinide/ metformin)

**DIABETES – ORAL HYPOGLYCEMICS, SULFONYLUREAS SECOND GENERATION**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
GLIMEPIRIDE (generic of Amaryl®) GLIPIZIDE (generic of Glucotrol®) GLIPIZIDE ER (generic of Glucotrol XL®) GLYBURIDE (generic of Diabeta®, Micronase®) GLYBURIDE MICRONIZED (generic of Glynase PressTabs®)		

**DIABETES – ORAL HYPOGLYCEMICS, THIAZOLIDINEDIONES**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
PIOGLITAZONE (generic of Actos®)		AVANDIA® (rosiglitazone)

**DIABETES – ORAL HYPOGLYCEMICS, THIAZOLIDINEDIONES /  
SULFONYLUREAS COMBINATION**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
		AVANDARYL® (glimepiride/ rosiglitazone) GLIMEPIRIDE/ PIOGLITAZONE (generic of Duetac®)

**DIABETES – ORAL HYPOGLYCEMICS, THIAZOLIDINEDIONES / DPP-4  
COMBINATION**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
		OSENI <sup>®</sup> (pioglitazone/alogliptin)

**DIABETES – ORAL HYPOGLYCEMICS, THIAZOLIDINEDIONES / BIGUANIDE COMBINATION**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
PIOGLITAZONE/METFORMIN (generic of ActoPlus Met <sup>®</sup> )	ACTOPLUS MET XR <sup>®</sup> (pioglitazone/metformin)	AVANDAMET <sup>®</sup> (rosiglitazone/ metformin)

**DIABETES – ORAL HYPOGLYCEMICS, SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
		INVOKANA <sup>®</sup> (canagliflozin)

**DIABETES – ORAL HYPOGLYCEMICS, LIPOTROPIC/DPP-4 COMBINATION**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
	JUVISYNC <sup>®</sup> (sitagliptin/ simvastatin)	

## Endocrine Agents: Estrogenic Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. The requested medication may be approved if there has been a therapeutic failure to at least two trials of thirty days each with medications not requiring prior approval

### ENDOCRINE AGENTS: ESTROGENS – ORAL ESTROGENS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CENESTIN <sup>®</sup> (synthetic conjugated estrogens) ENJUVA <sup>®</sup> (synthetic conjugated estrogens) ESTRADIOL (generic of Estrace <sup>®</sup> ) ESTROPIPATE MENEST <sup>®</sup> (esterified estrogens) PREMARIN <sup>®</sup> (conjugated estrogens)	FEMTRACE <sup>®</sup> (estradiol)

### ENDOCRINE AGENTS: ESTROGENS – ORAL ESTROGEN/PROGESTERONE COMBINATIONS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ETHINYL ESTRADIOL/NORETHINDRONE ACETATE (generic of FemHRT <sup>®</sup> ) FEMHRT <sup>®</sup> (norethindrone/ethinylestradiol) PREMPHASE <sup>®</sup> (medroxyprogesterone/estrogens conjugated) PREMPRO <sup>®</sup> (medroxyprogesterone/estrogens conjugated)	ANGELIQ <sup>®</sup> (drospirenone/estradiol) ESTRADIOL/NORETHINDRONE ACETATE tablets (generic of Activella <sup>®</sup> ) PREFEST <sup>®</sup> (estradiol/norgestimate)

### ENDOCRINE AGENTS: ESTROGENS – TRANSDERMAL ESTROGENS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ALORA <sup>®</sup> patch (estradiol) ESTRADIOL patch (generic of Climara <sup>®</sup> )	DIVIGEL <sup>®</sup> transdermal gel (estradiol) ELESTRIN <sup>®</sup> transdermal gel (estradiol) ESTRASORB <sup>®</sup> transdermal emulsion (estradiol) EVAMIST <sup>®</sup> transdermal solution (estradiol) MENOSTAR <sup>®</sup> patch (estradiol) MINIVELLE <sup>®</sup> patch (estradiol) VIVELLE-DOT <sup>®</sup> patch (estradiol)

### ENDOCRINE AGENTS: ESTROGENS – TRANSDERMAL ESTROGEN/PROGESTERONE COMBINATIONS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
COMBIPATCH <sup>®</sup> (estradiol/norethindrone)	CLIMARA PRO <sup>®</sup> (estradiol/levonorgestrel oral)

### ENDOCRINE AGENTS: ESTROGENS – VAGINAL ESTROGENS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ESTRING <sup>®</sup> vaginal ring (estradiol) PREMARIN <sup>®</sup> vaginal cream (estrogens conjugated)	ESTRACE <sup>®</sup> vaginal cream (estradiol) FEMRING <sup>®</sup> vaginal ring (estradiol) VAGIFEM <sup>®</sup> vaginal tablet (estradiol)

## Endocrine Agents: Growth Hormone

**LENGTH OF AUTHORIZATIONS:** varies as listed below.

- All products in this class require clinical prior authorization
- Must be treated and followed by a pediatric endocrinologist, pediatric nephrologist, clinical geneticist, endocrinologist or gastroenterologist (as appropriate for diagnosis)

**PDL CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

The requested medication may be approved if the following is true:

- If there has been a therapeutic failure to no less than a three-month trial of at least one preferred medication

**CLINICAL CRITERIA**

Children - initial approval for the following diagnoses:

1. Growth Hormone Deficiency (GHD) – 6 month approval:
  - a. Acquired GHD due to cranial irradiation, panhypopituitarism, central nervous system tumors, trauma, radiation, or pituitary damage; OR
  - b. GHD with all the following:
    - i. Must be evaluated, therapy prescribed and monitored by a pediatric endocrinologist; and
    - ii. Must not have attained epiphyseal closure (documented by X-ray); and
    - iii. Must have failed to respond to TWO standard GH stimulation tests (with insulin, levodopa, arginine, propranolol, clonidine, or glucagon; may be done in the same session) defined as a peak measure GH level of less than 10ng/ml after stimulation; and
    - iv. Height at initiation of therapy must be > 2 standard deviations below population normal mean height for age and sex; and
    - v. Bone age is  $\geq 2$  years behind chronological age
2. Genetic diagnosis – 1 year approval:
  - a. Krause-Kivlin Syndrome; or
  - b. Turner Syndrome; or
  - c. Prader-Willi Syndrome; or
  - d. Noonan Syndrome
3. Short stature associated with Chronic Renal Insufficiency PRIOR to kidney transplant – 6 month approval (AACE does not recommend GH for post-transplantation).
4. SHOX – Short Stature Homeobox Gene deficiency
  - a. Diagnosis documented by chromosome analysis; and
  - b. Must not have attained epiphyseal closure (documented by X-ray); and
  - c. Height at initiation of therapy must be > 2 standard deviations below population normal mean height for age and sex; and
  - d. Bone age is  $\geq 2$  years behind chronological age

5. Small for gestational age (intrauterine growth restriction) – 1 year approval:
  - a. Birth weight or length is  $\geq 2$  SD below the mean for gestational age; and
  - b. Child fails to manifest catch-up growth by age of 2 years, defined as a height  $\geq 2$  SD below the mean for age and sex; and
  - c. Age is no less than 24 months and no more than 48 months
6. Reauthorization– 1 year approval:
  - a. Acquired GHD or genetic syndrome diagnosis; or
  - b. Growth Hormone Deficiency, Small for Gestational Age and SHOX
    - i. Must not have attained epiphyseal closure (documented by X-ray)
    - ii. Increase in growth double the annualized pre-treatment growth rate within first six months, then at least 3cm per year thereafter

Adults - initial approval for the following diagnoses:

1. AIDS-related wasting or cachexia – 6 month approval
  - a. Diagnosis; and
  - b. Involuntary weight loss of  $>10\%$  from baseline or BMI  $< 20$ ; and
  - c. Patient has not responded to high-calorie diet; and
  - d. Patient is being treated with antiretroviral drugs
2. Short bowel syndrome – 6 month approval
  - a. Diagnosis by gastroenterologist; and
  - b. Patient receiving intravenous nutritional support
3. Pituitary damage – 1 year approval
  - a. Acquired GHD due to cranial irradiation, panhypopituitarism, central nervous system tumors, trauma, radiation, or pituitary damage; OR
  - b. Must have failed to respond to TWO standard GH stimulation tests (with insulin, levodopa, arginine, propranolol, clonidine, or glucagon; may be done in the same session) defined as a peak measure GH level of less than 5 ng/ml after stimulation
4. Reauthorization: The patient health status has improved since last approval (weight gain, improved body composition)
  - a. AIDS-related wasting or cachexia or short bowel syndrome – 6 months
  - b. Pituitary damage or genetic syndrome – 1 year

**GROWTH HORMONES**

CLINICAL PA REQUIRED “PREFERRED”	PA REQUIRED
GENOTROPIN <sup>®</sup> cartridge, Miniquick (somatropin) NORDITROPIN <sup>®</sup> cartridge, FlexPro, NordiFlex, vial (somatropin)	HUMATROPE <sup>®</sup> cartridge, vial (somatropin) NUTROPIN AQ <sup>®</sup> cartridge, Nuspin, vial (somatropin) NUTROPIN <sup>®</sup> vial (somatropin) OMNITROPE <sup>®</sup> cartridge, vial (somatropin) SAIZEN <sup>®</sup> cartridge, vial (somatropin) SEROSTIM <sup>®</sup> vial (somatropin) TEV-TROPIN <sup>®</sup> vial (somatropin) ZORBTIVE <sup>®</sup> vial (somatropin)

## Endocrine Agents: Osteoporosis – Bone Ossification Enhancers

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval

**CRITICAL INFORMATION**

Patients should only be on ONE of the therapeutic classes (bisphosphonates, calcitonin-salmon).

**ENDOCRINE AGENTS: OSTEOPOROSIS - BONE OSSIFICATION ENHANCERS - ORAL BISPHOSPHONATES**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ALENDRONATE tablets (generic of Fosamax®)	ACTONEL® (risedronate) ALENDRONATE ORAL SOLN 70mg/75ml (generic of Fosamax®) ATELVIA® (risedronate) BINOSTO® (alendronate sodium effervescent tablet) ETIDRONATE (generic of Didronel®) FOSAMAX PLUS D™ (alendronate/cholecalciferol) FOSAMAX® ORAL SOLN 70mg/75ml (alendronate) IBANDRONATE (generic of Boniva®) SKELID® (tiludronate)

**ENDOCRINE AGENTS: OSTEOPOROSIS - BONE OSSIFICATION ENHANCERS - CALCITONIN-SALMON**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	CALCITONIN-SALMON (generic of Miacalcin®) FORTICAL® (calcitonin salmon)

## Gastrointestinal Agents: Anti-Emetics

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval

### **GASTROINTESTINAL AGENTS: ANTI-EMETIC AGENTS**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
EMEND <sup>®</sup> tablets, trifold (aprepitant) ONDANSETRON tablets, solution, ODT (generic of Zofran <sup>®</sup> )	ANZEMET <sup>®</sup> (dolasetron) GRANISETRON tablet, solution (generic of Kytril <sup>®</sup> ) SANCUSO <sup>®</sup> patch (granisetron)

## Gastrointestinal Agents: Irritable Bowel Syndrome / Chronic Constipation Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
  
2. The requested medication may be approved if there has been a therapeutic failure to no less than a two-week trial of at least two medications not requiring prior approval

**GASTROINTESTINAL AGENTS: CHRONIC CONSTIPATION AGENTS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
POLYETHYLENE GLYCOL (generic of Miralax <sup>®</sup> ) BISACODYL (generic of Dulcolax <sup>®</sup> ) SENNA (generic of Senokot <sup>®</sup> ) CASANTHRANOL/DOCUSATE SODIUM (generic of Peri-Colace <sup>®</sup> )	AMITIZA <sup>®</sup> (lubiprostone) LINZESS <sup>™</sup> (linaclotide)

## Gastrointestinal Agents: H. Pylori Packages

**LENGTH OF AUTHORIZATIONS:** 1 course of treatment

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval

**Also consider whether components are appropriate vs. package**

### GASTROINTESTINAL AGENTS: H. PYLORI PACKAGES

NO PA REQUIRED "PREFERRED"	PA REQUIRED
HELIDAC <sup>®</sup> (metronidazole/tetracycline/bismuth subsalicylate)	OMECLAMOX-PAK <sup>®</sup> (omeprazole/clarithromycin/amoxicillin) PREVPAC <sup>®</sup> (lansoprazole/amoxicillin/clarithromycin) PYLERA <sup>®</sup> (metronidazole/tetracycline/bismuth subsalicylate)

## Gastrointestinal Agents: Pancreatic Enzymes

**LENGTH OF AUTHORIZATIONS:** 1 year

Is there any reason the patient cannot be changed to a medication not requiring prior approval?  
Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### **ADDITIONAL INFORMATION**

The requested medication may be approved if both of the following are true:

- If there has been a therapeutic failure to no less than a one-month trial of at least one medication not requiring prior approval

### **GASTROINTESTINAL AGENTS: PANCREATIC ENZYMES**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
CREON <sup>®</sup> (pancrelipase) PANCRELIPASE 5000 ZENPEP <sup>®</sup> (pancrelipase)	PANCREAZE <sup>®</sup> (pancrelipase) PERTZYE <sup>®</sup> (pancrelipase) ULTRESA <sup>®</sup> (pancrelipase) VIOKACE <sup>®</sup> (pancrelipase)

## Gastrointestinal Agents: Proton Pump Inhibitors

**LENGTH OF AUTHORIZATIONS:** 6 months, except as listed under clinical criteria

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If there has been a therapeutic failure to no less than a one-month trial of at least one medication not requiring prior approval, then may approve the requested medication.
3. If a medication requiring prior approval was initiated in the hospital for the treatment of a condition such as a GI bleed, may approve the requested medication.

**ADDITIONAL INFORMATION**

- No PA needed for preferred PPI at once-daily dosing
- No PA needed for preferred PPI at any dose for age under 21
- Must have therapeutic failure on preferred agent before PA of non-preferred

**CLINICAL CRITERIA FOR PPI DOSES GREATER THAN ONCE DAILY**

1. For diagnosis of H. Pylori, BID dosing may be authorized for 1 month
2. For diagnosis of COPD, Dyspepsia, Gastritis, Gastroparesis, Symptomatic Uncomplicated Barrett’s Esophagus, Carcinoma of GI tract, Crest Syndrome, Esophageal Varices, Scleroderma, Systemic Mastocytosis, Zollinger Ellison Syndrome:
  - Length of authorization: 1 year
  - Criteria for approval: Must have failed QD dosing

**GASTROINTESTINAL AGENTS: PPIs**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
LANSOPRAZOLE capsules (generic of Prevacid®)	ACIPHEX® (rabeprazole)
LANSOPRAZOLE ODT (generic of Prevacid SoluTab®) (No PA required for age 6 or under)	DEXILANT® (dexlansoprazole)
OMEPRAZOLE capsules (generic of Prilosec®)	ESOMEPRAZOLE STRONTIUM
OMEPRAZOLE tablets (generic of Prilosec OTC®)	LANSOPRAZOLE ODT (generic of Prevacid SoluTab®) (PA required for age over 6)
PANTOPRAZOLE (generic of Protonix®)	NEXIUM® capsules (esomeprazole)
PREVACID 24 HOUR® (OTC) (lansoprazole)	NEXIUM® packets (esomeprazole)
PRILOSEC OTC® tablets (omeprazole)	OMEPRAZOLE/SODIUM BICARBONATE
ZEGERID OTC® (omeprazole/sodium bicarbonate)	PRILOSEC® suspension (omeprazole)
	PROTONIX® suspension

## Gastrointestinal Agents: Ulcerative Colitis Agents

**LENGTH OF AUTHORIZATIONS:** 6 months

**STEP THERAPY:** Oral agents only

- 1) For a preferred brand oral agent, there must have been inadequate clinical response to preferred generic oral alternatives, including a trial of no less than one month of at least one preferred generic
- 2) For a non-preferred oral agent, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands

**OTHER CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**ADDITIONAL INFORMATION**

1. Ulcerative Colitis Agents are available in both oral (IR, ER) and rectal (enema, suppository) formulations. Patients with mild or moderate disease may be treated with either rectal or oral agents.
2. The efficacy among the different 5-ASA derivatives appears to be comparable.

### GASTROINTESTINAL AGENTS: ULCERATIVE COLITIS AGENTS - ORAL

NO PA REQUIRED "PREFERRED"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
BALSALAZIDE DISODIUM (generic of Colazal <sup>®</sup> ) SULFASALAZINE (generic of Azulfidine <sup>®</sup> ) SULFASALAZINE EC (generic of Azulfidine Entab <sup>®</sup> )	APRISO <sup>®</sup> (mesalamine) DELZICOL <sup>®</sup> (mesalamine) LIALDA <sup>®</sup> (mesalamine) PENTASA <sup>®</sup> (mesalamine)	ASACOL HD <sup>®</sup> (mesalamine) DIPENTUM <sup>®</sup> (olsalazine) GIAZO <sup>®</sup> (balsalazide disodium)

### GASTROINTESTINAL AGENTS: ULCERATIVE COLITIS AGENTS - RECTAL

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CANASA <sup>®</sup> suppositories (mesalamine) MESALAMINE enema (generic of Rowasa <sup>®</sup> and SFRowasa <sup>®</sup> )	MESALAMINE enema kit (generic for Rowasa <sup>®</sup> kit)

## Genitourinary Agents: Benign Prostatic Hyperplasia

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindications to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. Patient must have a therapeutic failure to no less than a one-month trial on at least one medication not requiring prior approval.

**ADDITIONAL CRITERIA FOR APPROVAL OF TADALAFIL (CIALIS®):**

Patient must have diagnosis of benign prostatic hyperplasia

**BENIGN PROSTATIC HYPERPLASIA AGENTS – ALPHA-1 ADRENERGIC BLOCKERS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
DOXAZOSIN (generic of Cardura®) PRAZOSIN (generic of Minipress®) TAMSULOSIN (generic of Flomax®) TERAZOSIN (generic of Hytrin®)	ALFUZOSIN (generic of Uroxatral®) CARDURA® XL (doxazosin) RAPAFLO® (silodosin)

**BENIGN PROSTATIC HYPERPLASIA AGENTS – 5-ALPHA REDUCTASE INHIBITORS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
FINASTERIDE (generic of Proscar®)	AVODART® (dutasteride)

**BENIGN PROSTATIC HYPERPLASIA AGENTS – COMBINATION 5-ALPHA REDUCTASE INHIBITOR/ALPHA-1 ADRENERGIC BLOCKER**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
	JALYN® (dutasteride/tamsulosin)

**BENIGN PROSTATIC HYPERPLASIA AGENTS – PHOSPHODIESTERASE TYPE 5 INHIBITORS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
	CIALIS® (tadalafil) 2.5mg, 5mg only *

\* Note: Clinical PA required for Cialis®. Patient must have diagnosis of benign prostatic hyperplasia.

## Genitourinary Agents: Electrolyte Depletter Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY:**

- 1) For a preferred brand agent, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one week of at least one preferred generic
- 2) For a non-preferred agent, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one week each of at least two preferred generics or brands

**OTHER CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**CLINICAL INFORMATION**

Calcium acetate products may lead to hypercalcemia. This agent is recommended in patients with normal serum calcium levels.

**ELECTROLYTE DEPLETERS FOR HYPERPHOSPHATEMIA**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
CALCIUM ACETATE (generic of PhosLo <sup>®</sup> gelcap) CALCIUM CARBONATE CALPHRON <sup>®</sup> (calcium acetate) ELIPHOS <sup>®</sup> (calcium acetate) PHOSLO <sup>®</sup> (calcium acetate)	MAGNEBIND <sup>®</sup> (calcium carbonate/ magnesium carbonate/folic acid) RENAGEL <sup>®</sup> (sevelamer)	REVELA <sup>®</sup> (sevelamer) FOSRENOL <sup>®</sup> (lanthanum carbonate) PHOSLYRA <sup>®</sup> solution (calcium acetate)

## Genitourinary Agents: Urinary Antispasmodics

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY:**

- For a preferred brand agent, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one month of at least one preferred generic
- For a non-preferred agent, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands
- Patients under age 18 may be approved for Detrol® LA or Gelnique® if there was inadequate clinical response to a trial of no less than one month of oxybutynin (IR or ER).

**OTHER CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindications to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**GENITOURINARY AGENTS: URINARY ANTISPASMODICS**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
OXYBUTYNIN ER (generic of Ditropan® XL) OXYBUTYNIN syrup (generic of Ditropan®) OXYBUTYNIN tablets (generic of Ditropan®) SANCTURA® (trospium) SANCTURA XR® (trospium)	ENABLEX® (darifenacin) OXYTROL® patch (oxybutynin) VESICARE® (solifenacin)	DETROL® LA (tolterodine) GELNIQUE® (oxybutynin) MYRBETRIQ® (mirabegron) TOLTERODINE (generic of Detrol®) TOVIAZ® (fesoterodine) TROSPIUM (generic of Sanctura®) TROSPIUM ER (generic of Sanctura® XR)

# Immunomodulator Agents for Systemic Inflammatory Disease

**LENGTH OF AUTHORIZATIONS:** 1 year

All products in this class require clinical prior authorization:

- No current infection; and
- Prior first-generation therapy appropriate for diagnosis; and
- Diagnosis of one of the following:
  - Rheumatoid Arthritis
  - Psoriatic Arthritis
  - Polyarticular Juvenile Idiopathic Arthritis
  - Crohn's Disease
  - Ankylosing Spondylitis
  - Psoriasis

**PDL CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**ADDITIONAL INFORMATION**

The requested medication may be approved if the following is true:

- If there has been a therapeutic failure to no less than a three-month trial of at least one preferred medication

**ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR**

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED
CIMZIA <sup>®</sup> syringe (certolizumab pegol)	SIMPONI <sup>™</sup> pen, syringe (golimumab)
ENBREL <sup>®</sup> kit, SureClik, syringe (etanercept)	ORENCIA <sup>®</sup> syringe (abatacept)
HUMIRA <sup>®</sup> pen, starter packs, syringe (adalimumab)	

**ANTI-INFLAMMATORY INTERLEUKIN-1 RECEPTOR ANTAGONIST**

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED
	KINERET <sup>®</sup> syringe (anakinra)

**JANUS KINASE INHIBITOR**

CLINICAL PA REQUIRED "PREFERRED"	PA REQUIRED
	XELJANZ <sup>®</sup> tablet (tofacitinib citrate)

## Infectious Disease Agents: Antibiotics – Cephalosporins

**LENGTH OF AUTHORIZATIONS:** for the date of service only; no refills

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If the infection is caused by an organism resistant to medications not requiring prior approval, then may approve the requested medication.
  - Note diagnosis and any culture and sensitivity reports
3. If there have been therapeutic failures to no less than a three-day trial of at least one medication not requiring prior approval, then may approve the requested medication.

### **ADDITIONAL INFORMATION TO AID IN THE FINAL DECISION**

If the patient is completing a course of therapy with a medication requiring prior approval, which was initiated in the hospital, then may approve the requested medication to complete the course of therapy.

### **CEPHALOSPORINS, FIRST GENERATION – CAPSULES AND TABLETS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CEFADROXIL (generic of Duricef®) CEPHALEXIN 250mg, 500 mg (generic of Keflex®)	CEPHALEXIN 750mg (generic of Keflex®)

### **CEPHALOSPORINS, FIRST GENERATION – SUSPENSIONS AND LIQUIDS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CEFADROXIL suspension (generic of Duricef®) CEPHALEXIN suspension (generic of Keflex® Suspension)	

### **CEPHALOSPORINS, SECOND GENERATION – CAPSULES AND TABLETS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CEFACLOR (generic of Ceclor®) CEFACLOR ER (generic of Ceclor CD®) CEFPROZIL (generic of Cefzil®) CEFUROXIME (generic of Ceftin®)	

### **CEPHALOSPORINS, SECOND GENERATION – SUSPENSIONS AND LIQUIDS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CEFACLOR suspension (no PA required for age 12 or under) (generic of Ceclor®) CEFTIN® suspension (no PA required for age 12 or under) (cefuroxime) CEFPROZIL suspension (generic of Cefzil®) (no PA required for age 12 or under)	CEFACLOR suspension (PA required for age over 12) (generic of Ceclor®) CEFTIN® suspension (PA required for age over 12) (cefuroxime) CEFPROZIL suspension (generic of Cefzil®) (PA required for age over 12)

### **CEPHALOSPORINS, THIRD GENERATION – CAPSULES AND TABLETS**

<b>NO PA REQUIRED “PREFERRED”</b>	<b>PA REQUIRED</b>
CEFDINIR (generic of Omnicef®)	CEDAX® (ceftibuten) CEFDITOREN PIVOXIL (generic of Spectracef®) CEFPODOXIME (generic of Vantin®) SUPRAX® (cefixime)

### **CEPHALOSPORINS, THIRD GENERATION – SUSPENSIONS AND LIQUIDS**

<b>NO PA REQUIRED “PREFERRED”</b>	<b>PA REQUIRED</b>
CEFDINIR suspension (generic of Omnicef®)	CEDAX® suspension (ceftibuten) SUPRAX® suspension (cefixime) CEFPODOXIME suspension (generic of Vantin®)

## Infectious Disease Agents: Antibiotics – Macrolides

**LENGTH OF AUTHORIZATIONS:** for the date of service only; no refills

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If the infection is caused by an organism resistant to medications not requiring prior approval, then may approve the requested medication.
  - Note diagnosis and any culture and sensitivity reports
3. If there has been a therapeutic failure to no less than a three-day trial of at least one medication not requiring prior approval, then may approve the requested medication.

**ADDITIONAL INFORMATION TO AID IN THE FINAL DECISION**

If the patient is completing a course of therapy with a medication requiring prior approval, which was initiated in the hospital, then may approve the requested medication to complete the course of therapy.

**INFECTIOUS DISEASE AGENTS: MACROLIDES - ORAL**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
AZITHROMYCIN tablets and suspension (generic of Zithromax®)	PCE® (erythromycin base)
CLARITHROMYCIN ER (generic of Biaxin XL®)	ZMAX™ (azithromycin ER) for oral suspension
CLARITHROMYCIN tablets and suspension (generic of Biaxin®)	
ERYPED® (erythromycin ethylsuccinate)	
ERY-TAB® (erythromycin base)	
ERYTHROCIN STEARATE® (erythromycin stearate)	
ERYTHROMYCIN BASE	
ERYTHROMYCIN ETHYLSUCCINATE	
ERYTHROMYCIN W/SULFISOXAZOLE	

## Infectious Disease Agents: Antibiotics – Quinolones

**LENGTH OF AUTHORIZATIONS:** for the date of service only; no refills

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If the infection is caused by an organism resistant to medications not requiring prior approval, then may approve the requested medication.
  - Note diagnosis and any culture and sensitivity reports
3. If there has been a therapeutic failure to at least a three-day trial of at least one medication not requiring prior approval, then may approve the requested medication.

**ADDITIONAL INFORMATION TO AID IN THE FINAL DECISION**

1. If the patient is completing a course of therapy with a medication requiring prior approval, which was initiated in the hospital, then may approve the requested medication to complete the course of therapy.
2. If the prescriber expresses concern over safety issues of a preferred agent, a non-preferred agent may be approved.

**INFECTIOUS DISEASE AGENTS: QUINOLONES, SECOND GENERATION - ORAL**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CIPROFLOXACIN (generic of Cipro <sup>®</sup> ) CIPRO <sup>®</sup> suspension (no PA required for age 12 or under) (ciprofloxacin) OFLOXACIN (generic of Floxin <sup>®</sup> )	CIPRO <sup>®</sup> suspension (PA required for age over 12) (ciprofloxacin) CIPROFLOXACIN ER (generic of Cipro <sup>®</sup> XR) NOROXIN <sup>®</sup> (norfloxacin) PROQUIN <sup>®</sup> XR (ciprofloxacin)

**INFECTIOUS DISEASE AGENTS: QUINOLONES, THIRD GENERATION - ORAL**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
LEVOFLOXACIN (generic of Levaquin <sup>®</sup> )	AVELOX <sup>®</sup> (moxifloxacin) AVELOX ABC PACK <sup>®</sup> (moxifloxacin)

**INFECTIOUS DISEASE AGENTS: QUINOLONES, FOURTH GENERATION - ORAL**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	FACTIVE <sup>®</sup> (gemifloxacin)

## Infectious Disease Agents: Antifungals for Onychomycosis & Systemic Infections

**LENGTH OF AUTHORIZATIONS:** For the duration of the prescription (up to 6 months)

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug-to-drug interaction with medications not requiring prior approval:
    - Drug interactions (inhibition of CYP450 system)
    - Ketoconazole > Itraconazole > Voriconazole > Fluconazole
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If the patient has a serious illness that causes them to be immunocompromised [i.e. AIDS, cancer, organ (solid or non-solid) transplant] then may approve the requested medication.

### **ADDITIONAL INFORMATION TO AID IN THE FINAL DECISION**

1. If the patient is completing a course of therapy with a medication requiring prior approval, which was initiated in the hospital or other similar location, or if the patient has just become Medicaid eligible and is already on a course of treatment with a medication requiring prior approval, then may approve the requested medication.
2. If the request is for a diagnosis other than fungal infection, please refer the case to a pharmacist. An off label use may be approvable for a medication such as Nizoral® for advanced prostate cancer or for Cushing's Syndrome when standard treatments have failed.

### **INFECTIOUS DISEASE AGENTS: AGENTS FOR ONYCHOMYCOSIS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
GRIFULVIN®V tablets (griseofulvin, microsize) GRISEOFULVIN suspension (generic of Grifulvin®V) GRIS-PEG® (griseofulvin, ultramicrosize) TERBINAFINE (generic of Lamisil®)	ITRACONAZOLE (generic of Sporanox®) LAMISIL Granules (terbinafine) ONMEL® (itraconazole) SPORANOX® 100mg/10ml oral solution (itraconazole)

### **INFECTIOUS DISEASE AGENTS: AGENTS FOR SYSTEMIC INFECTIONS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
FLUCONAZOLE (generic of Diflucan®) FLUCONAZOLE suspension (generic of Diflucan®) KETOCONAZOLE (generic of Nizoral®)	ITRACONAZOLE CAPSULES (generic of Sporanox®) NOXAFIL® (posaconazole) SPORANOX® 100mg/10ml oral solution (itraconazole)

## Infectious Disease Agents: Antivirals – Hepatitis C Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

Is there any reason the patient cannot be changed to a medication within the same class which does not require prior approval? Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**ADDITIONAL INFORMATION TO AID IN THE FINAL DECISION**

- Pegylated Interferons have a Black Box Warning which indicates that a patient should be monitored closely with periodic clinical and laboratory evaluations.
- Ribavirins are contraindicated in women who are pregnant and in their male partner(s). At least two reliable forms of contraception must be used during therapy.

**ADDITIONAL CRITERIA FOR PROTEASE INHIBITORS:**

Patient is receiving prior/concurrent interferon and ribavirin as recommended in the FDA-approved package labeling

**INFECTIOUS DISEASE AGENTS: HEPATITIS C - PEGYLATED INTERFERONS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
PEGASYS <sup>®</sup> (peginterferon alfa-2a) PEGASYS CONVENIENCE PACK <sup>®</sup> (peginterferon alfa-2a) PEG-INTRON <sup>®</sup> (peginterferon alfa-2b) PEG-INTRON REDIPEN <sup>®</sup> (peginterferon alfa-2b)	

**INFECTIOUS DISEASE AGENTS: HEPATITIS C - RIBAVIRINS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
RIBAVIRIN (generic of Rebetol <sup>®</sup> )	COPEGUS <sup>®</sup> (ribavirin) REBETOL <sup>®</sup> (ribavirin) RIBAPAK <sup>®</sup> (ribavirin) RIBASPHERE <sup>®</sup> (ribavirin) 400mg, 600mg

**INFECTIOUS DISEASE AGENTS: HEPATITIS C – PROTEASE INHIBITORS**

CLINICAL PA REQUIRED “PREFERRED”	PA REQUIRED
INCIVEK <sup>®</sup> (telaprevir) VICTRELIS <sup>®</sup> (boceprevir)	

## Infectious Disease Agents: Antivirals – Herpes

**LENGTH OF AUTHORIZATIONS:** For the duration of the prescription (up to 6 months)

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### **INFECTIOUS DISEASE AGENTS: ANTIVIRALS - HERPES**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
ACYCLOVIR (generic of Zovirax®) VALACYCLOVIR (generic of Valtrex®)	FAMCICLOVIR (generic of Famvir®)

## Infectious Disease Agents: Antivirals – HIV

**LENGTH OF AUTHORIZATIONS:** 1 year

**GRANDFATHERING:**

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the drug through the automated PA system. Patients who have taken the drug in the previous 120 days, but do not have claims history (new to Medicaid, samples, etc.), will be approved for PA after prescriber contact.

**OTHER CRITERIA:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. Has the patient failed a therapeutic trial of at least one month with at least one medication not requiring prior approval?

**HIV PROTEASE INHIBITORS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CRIXIVAN <sup>®</sup> (indinavir sulfate) INVIRASE <sup>®</sup> (saquinavir mesylate) KALETRA <sup>®</sup> (lopinavir/ritonavir) LEXIVA <sup>®</sup> (fosamprenavir calcium) NORVIR <sup>®</sup> (ritonavir) REYATAZ <sup>®</sup> (atazanavir sulfate) VIRACEPT <sup>®</sup> (nelfinavir mesylate)	

**HIV NON-PEPTIDIC PROTEASE INHIBITORS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
PREZISTA <sup>®</sup> (darunavir ethanolate)	APTIVUS <sup>®</sup> (tipranavir; tipranavir/vitamin E)

**HIV REVERSE TRANSCRIPTASE INHIBITORS, NUCLEOSIDE ANALOGS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ABACAVIR SULFATE tablet (generic of Ziagen <sup>®</sup> ) DIDANOSINE capsule (generic of Videx <sup>®</sup> ) EMTRIVA <sup>®</sup> (emtricitabine) EPIVIR <sup>®</sup> solution EPZICOM <sup>®</sup> (abacavir/lamivudine) LAMIVUDINE tablet (generic of Epivir <sup>®</sup> ) LAMIVUDINE/ZIDOVUDINE (generic of Combivir <sup>®</sup> ) STAVUDINE (generic of Zerit <sup>®</sup> ) TRIZIVIR <sup>®</sup> (abacavir/lamivudine/zidovudine) VIDEX <sup>®</sup> solution (didanosine) ZIAGEN <sup>®</sup> solution (abacavir sulfate) ZIDOVUDINE (generic of Retrovir <sup>®</sup> )	

**HIV REVERSE TRANSCRIPTASE INHIBITORS, NUCLEOTIDE ANALOGS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
VIREAD <sup>®</sup> (tenofovir disoproxil fumarate)	

## HIV REVERSE TRANSCRIPTASE INHIBITORS, NON-NUCLEOSIDE ANALOGS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
NEVIRAPINE IR (generic of Viamune®) SUSTIVA® (efavirenz) VIRAMUNE® XR (nevirapine)	EDURANT® (rilpivirine) INTELENCE® (etravirine) RESCRIPTOR® (delavirdine mesylate)

## HIV INTEGRASE STRAND TRANSFER INHIBITORS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ISENTRESS® (raltegravir potassium)	

## HIV CCR5 CO-RECEPTOR ANTAGONISTS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	SELZENTRY® (maraviroc)

## HIV FUSION INHIBITORS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
	FUZEON® (enfuvirtide)

## HIV RTI, NUCLEOSIDE-NUCLEOTIDE ANALOGS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
TRUVADA® (emtricitabine/tenofovir)	

## HIV RTI, NUCLEOSIDE, NUCLEOTIDE, & NON-NUCLEOSIDE ANALOGS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ATRIPLA® (emtricitabine/efavirenz/tenofovir) COMPLERA® (emtricitabine/rilpivirine/tenofovir)	

## HIV INTEGRASE INHIBITOR & RTI COMBINATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
STRIBILD® (elvitegravir/cobicistat/emtricitabine/ tenofovir)	

## Ophthalmic Agents: Antibiotic and Antibiotic-Steroid Combination Drops and Ointments

**LENGTH OF AUTHORIZATIONS:** for the date of service only; no refills for acute infection. Refills for up to 14 days may be authorized for quinolones only for patients undergoing surgery.

**STEP THERAPY:**

- 1) For a preferred brand agent, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than three days of at least one preferred generic
- 2) For a non-preferred agent, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than three days each of at least two preferred generics or brands

**OTHER CRITERIA:**

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If the infection is caused by an organism resistant to medications not requiring prior approval, then may approve the requested medication.
  - Note diagnosis and any culture and sensitivity reports

**OPHTHALMIC AGENTS: ANTIBACTERIAL - QUINOLONES**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
CIPROFLOXACIN drops (generic of Ciloxan <sup>®</sup> ) OFLOXACIN drops (generic of Ocuflax <sup>®</sup> )	CILOXAN <sup>®</sup> ointment (ciprofloxacin) VIGAMOX <sup>®</sup> drops (moxifloxacin)	BESIVANCE <sup>®</sup> drops (besifloxacin) LEVOFLOXACIN drops (generic of Quixin <sup>®</sup> ) MOXEZA <sup>®</sup> drops (moxifloxacin) ZYMAXID <sup>®</sup> drops (gatifloxacin)

**OPHTHALMIC AGENTS: ANTIBACTERIAL – NON-QUINOLONE**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
BACITRACIN ointment BACITRACIN-POLYMYXIN ointment ERYTHROMYCIN ointment (generic of Ilotycin®) GENTAMICIN drops GENTAMICIN ointment NEOMYCIN/POLYMYXIN/BACITRACIN ointment (generic of Neosporin®) NEOMYCIN/POLYMYXIN/GRAMICIDIN drops (generic of Neosporin®) POLYMYXIN/TRIMETHOPRIM drops (generic of Polytrim®) SULFACETAMIDE drops TOBRAMYCIN drops (generic of Tobrex®)	TOBREX® ointment (tobramycin)	AZASITE® drops (azithromycin) SULFACETAMIDE ointment

**OPHTHALMIC AGENTS: ANTIBACTERIAL – STEROID COMBINATIONS**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
NEOMYCIN/POLYMYXIN/BACITRACIN/HYDROCORTISONE ointment NEOMYCIN/POLYMYXIN/DEXAMETHASONE drops (generic of Maxitrol®) NEOMYCIN/POLYMYXIN/DEXAMETHASONE ointment (generic of Maxitrol®) SULFACETAMIDE/PREDNISOLONE drops (generic of Vasocidin®) TOBRADEX® drops (dexamethasone/tobramycin)	BLEPHAMIDE® drops (prednisolone/sulfacetamide) BLEPHAMIDE® ointment (prednisolone/ sulfacetamide) PRED-G® drops (prednisolone/gentamicin) PRED-G® ointment (prednisolone/gentamicin) TOBRADEX® ointment (dexamethasone/tobramycin)	NEOMYCIN/POLYMYXIN/HYDROCORTISONE drops (generic of Cortisporin®) TOBRADEX ST® (dexamethasone/tobramycin) TOBRAMYCIN/DEXAMETHASONE drops (generic of TobraDex®) ZYLET® drops (tobramycin/loteprednol)

## Ophthalmic Agents: Antihistamines & Mast Cell Stabilizers

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindications to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. Patient must have a therapeutic failure to at least one of the preferred agents.

### OPHTHALMIC AGENTS: MAST CELL STABILIZERS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CROMOLYN (generic of Crolom <sup>®</sup> )	ALAMAST <sup>®</sup> (pemirolast) ALOCRIL <sup>®</sup> (nedocromil) ALOMIDE <sup>®</sup> (lodoxamide)

### OPHTHALMIC AGENTS: ANTIHISTAMINE/MAST CELL STABILIZERS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ALAWAY <sup>®</sup> (ketotifen) BEPREVE <sup>®</sup> (bepotastine) KETOTIFEN (generic of Alaway <sup>®</sup> , Zaditor <sup>®</sup> ) OPTIVAR <sup>®</sup> (azelastine) PATADAY <sup>™</sup> (olopatadine) ZADITOR <sup>®</sup> OTC (ketotifen)	AZELASTINE (generic of Optivar <sup>®</sup> ) EPINASTINE (generic of Elestat <sup>®</sup> ) EMADINE <sup>®</sup> (emedastine) LASTACAFT <sup>®</sup> (alcaftadine) PATANOL <sup>®</sup> (olopatadine)

## Ophthalmic Agents: Glaucoma Agents

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY: ACROSS ALL AGENTS**

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one month of at least one preferred generic
- 2) For a non-preferred agent, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands

**OTHER CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindications to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**OPHTHALMIC AGENTS: GLAUCOMA AGENTS – BETA BLOCKERS**

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
BETAXOLOL CARTEOLOL LEVOBUNOLOL (generic of Betagan®) METIPRANOLOL (generic of Optipranolol®) TIMOLOL gel solution (generic of Timoptic-XE®) TIMOLOL solution (generic of Timoptic®)	BETIMOL® (timolol)	BETOPTIC®S (betaxolol) ISTALOL™ (timolol)

**OPHTHALMIC AGENTS: GLAUCOMA AGENTS – PROSTAGLANDIN INHIBITORS**

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
LATANAPROST (generic of Xalatan®)	TRAVATAN®Z (travoprost)	LUMIGAN™ (bimatoprost) RESCULA® (unoprostone isopropyl) TRAVAPROST ZIOPTAN® (tafluprost)

**OPHTHALMIC AGENTS: GLAUCOMA AGENTS – ALPHA ADRENERGIC AGONISTS/SYPATHOMIMETICS**

NO PA REQUIRED “PREFERRED GENERIC”	STEP THERAPY REQUIRED “PREFERRED BRAND”	PA REQUIRED
BRIMONIDINE 0.2% ALPHAGAN®P (brimonidine 0.15%)	ALPHAGAN®P (brimonidine 0.1%)	APRACLONIDINE (generic of Iopidine®) BRIMONIDINE 0.15% (generic of Alphagan® P)

**OPHTHALMIC AGENTS: GLAUCOMA AGENTS – CARBONIC ANHYDRASE INHIBITORS**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
DORZOLAMIDE (generic of Trusopt®)	AZOPT® (brinzolamide)	

**OPHTHALMIC AGENTS: GLAUCOMA AGENTS – COMBINATION BETA BLOCKER AND ALPHA ADRENERGIC AGONIST**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
	COMBIGAN® (brimonidine/timolol)	

**OPHTHALMIC AGENTS: GLAUCOMA AGENTS – COMBINATION BETA BLOCKER AND CARBONIC ANHYDRASE INHIBITORS**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
DORZOLAMIDE/TIMOLOL (generic of Cosopt®)		COSOPT® PF (dorzolamide/timolol)

**OPHTHALMIC AGENTS: GLAUCOMA AGENTS – COMBINATION ALPHA-ADRENERGIC AGONIST AND CARBONIC ANHYDRASE INHIBITORS**

<b>NO PA REQUIRED “PREFERRED GENERIC”</b>	<b>STEP THERAPY REQUIRED “PREFERRED BRAND”</b>	<b>PA REQUIRED</b>
		SIMBRINZA™ (brinzolamide/brimonidine)

## Ophthalmic Agents: NSAIDs

**LENGTH OF AUTHORIZATIONS:** For the date of service only; no refills for acute use. Refills for up to 14 days may be authorized for patients undergoing surgery.

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### **ADDITIONAL INFORMATION**

The requested medication may be approved if both of the following are true:

- 1) If there has been a therapeutic failure to no less than a three-day trial of at least one medication not requiring prior approval
- 2) The requested medication's corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.

### **OPHTHALMIC NSAIDs**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
DICLOFENAC (generic of Voltaren <sup>®</sup> ) FLURBIPROFEN (generic of Ocufen <sup>®</sup> ) KETOROLAC (generic of Acular <sup>®</sup> , Acular LS <sup>®</sup> )	ACUVAIL <sup>®</sup> (ketorolac) BROMDAY <sup>®</sup> (bromfenac) BROMFENAC (generic of Xibrom <sup>®</sup> ) ILEVRO <sup>®</sup> (nepafenac) NEVANAC <sup>®</sup> (nepafenac) PROLENSA <sup>®</sup> (bromfenac)

## Otic Agents: Antibacterial and Antibacterial/Steroid Combinations

**LENGTH OF AUTHORIZATIONS:** For the date of service only; no refills for acute infection.

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If the infection is caused by an organism resistant to medications not requiring prior approval, then may approve the requested medication.
  - Note diagnosis and any culture and sensitivity reports

The requested medication may be approved if both of the following are true:

- If there has been a therapeutic failure to no less than a one-week trial of at least one medication not requiring prior approval
- The requested medication's corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.

### OTIC AGENTS: ANTIBACTERIAL – STERIOD COMBINATION

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CIPRODEX <sup>®</sup> suspension (ciprofloxacin with dexamethasone)	CIPRO HC <sup>®</sup> suspension (ciprofloxacin with hydrocortisone)
NEOMYCIN-POLYMYXIN B WITH HYDROCORTISONE solution (generic of Cortisporin <sup>®</sup> solution)	COLY-MYCIN-S <sup>®</sup> suspension (neomycin and colistin with hydrocortisone)
NEOMYCIN-POLYMYXIN B WITH HYDROCORTISONE suspension (generic of Cortisporin <sup>®</sup> suspension)	CORTISPORIN-TC <sup>®</sup> suspension (neomycin and colistin with hydrocortisone)
	PEDIOTIC <sup>®</sup> suspension (neomycin and polymyxin B with hydrocortisone)

### OTIC AGENTS: ANTIBACTERIAL

NO PA REQUIRED "PREFERRED"	PA REQUIRED
OFLOXACIN drops (generic of Floxin Otic <sup>®</sup> )	CIPROFLOXACIN (generic of Cetraxal <sup>®</sup> ) FLOXIN <sup>®</sup> singles (ofloxacin)

## Respiratory Agents: Antihistamines – Second Generation

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If there have been therapeutic failures after courses of treatment (e.g., one month for allergic rhinitis) with medication not requiring prior approval, then may approve the requested medication.

### **ADDITIONAL INFORMATION**

- Fexofenadine is indicated for patients 6 years of age and older
- Loratadine is indicated for patients 2 years of age and older
- Cetirizine and desloratadine are indicated for patients 6 months of age and older

### **RESPIRATORY AGENTS: ANTIHISTAMINES: SECOND GENERATION**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CETIRIZINE chewable (generic of Zyrtec®) (no PA required for age 6 or under)	ALAVERT® rapid dissolve (loratadine)
CETIRIZINE syrup (generic of Zyrtec®) (no PA required for age 6 or under)	ALAVERT® tablets (loratadine)
CETIRIZINE tablets (generic of Zyrtec®)	ALLEGRA® ODT (fexofenadrine)
CLARITIN® chewable (loratadine)	ALLEGRA® suspension (fexofenadrine)
LORATADINE rapid dissolve (generic of Claritin® Redi-tabs)	CETIRIZINE chewable (generic of Zyrtec®) (PA required for over age 6)
LORATADINE syrup (generic of Claritin® Syrup)	CETIRIZINE syrup (generic of Zyrtec®) (PA required for over age 6)
LORATADINE tablets (generic of Claritin®)	CLARINEX REDI-TABS® (desloratadine)
	CLARINEX® syrup (desloratadine)
	CLARITIN REDITABS® 5mg (loratadine)
	DESLORATADINE tablets (generic of Clarinex®)
	DESLORATADINE ODT (generic of Clarinex®)
	FEXOFENADINE (generic of Allegra®)
	LEVOCETIRIZINE (generic of Xyzal®)

### **RESPIRATORY AGENTS: ANTIHISTAMINE/DECONGESTANT COMBO: SECOND GENERATION**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
CETIRIZINE/PSEUDOEPHEDRINE (generic of Zyrtec- D®)	ALAVERT D-12HR® (loratadine/pseudoephedrine)
LORATADINE-D (generic of Claritin-D®)	ALLEGRA-D 24 HOUR® (fexofenadrine/pseudoephedrine)
	CLARINEX-D 12, 24 HOUR® (desloratadine/pseudoephedrine)
	FEXOFENADINE/PSEUDOEPHEDRINE (generic of Allegra-D 12 Hour®)

## Respiratory Agents: Beta-Adrenergic Agonists – Inhaled, Short Acting

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval within the same class and formulation? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. The requested medication may be approved if there has been a therapeutic failure to no less than a two-week trial of at least one medication not requiring prior approval within the same class and formulation. (i.e., nebulizers for nebulizers).

### RESPIRATORY AGENTS: BETA-ADRENERGIC, SHORT-ACTING

Metered Dose Inhalers or Other Devices

NO PA REQUIRED “PREFERRED”	PA REQUIRED
PROAIR <sup>®</sup> HFA (albuterol) PROVENTIL HFA <sup>®</sup> (albuterol) VENTOLIN HFA <sup>®</sup> (albuterol)	MAXAIR AUTOHALER <sup>®</sup> (pirbuterol) XOPENEX HFA <sup>®</sup> (levalbuterol)

### RESPIRATORY AGENTS: BETA-ADRENERGIC, SHORT-ACTING NEBULIZERS

NO PA REQUIRED “PREFERRED”	PA REQUIRED
ALBUTEROL (generic of Proventil <sup>®</sup> , Ventolin <sup>®</sup> ) 0.083% Premixed nebulizers, 0.5% Concentrated Solution ALBUTEROL 0.42mg/ml, 0.63mg/ml (generic of Accuneb <sup>®</sup> ) (no PA required for ages 12 and under)	ALBUTEROL 0.42mg/ml, 0.63mg/ml (generic of Accuneb <sup>®</sup> ) (PA required for over age 12) LEVALBUTEROL (generic of Xopenex <sup>®</sup> ) XOPENEX <sup>®</sup> (levalbuterol)

## Respiratory Agents: Beta-Adrenergic Agonists – Inhaled, Long Acting

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval within the same class and formulation? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. The requested medication may be approved if there has been a therapeutic failure to no less than a two-week trial of at least one medication not requiring prior approval within the same class and formulation. (i.e., nebulizers for nebulizers).

**STEP THERAPY REQUIRED** for all long-acting beta agonists and combinations:

Criteria	Approval Length
>= 3 claims for LABA (formoterol or salmeterol alone or in combination with steroid) in previous 6 months	6 months
>= 1 claim for anticholinergic (ipratropium, tiotropium, ipratropium/albuterol) in previous 6 months	12 months
>= 3 claims for inhaled corticosteroid (beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone) in previous 12 months	6 months
>= 3 claims for leukotriene modifier (montelukast, zafirlukast, zileuton) in previous 12 months	6 months
>= 3 claims for theophylline in previous 12 months	6 months
>= 3 claims for oral corticosteroid in previous 4 months	6 months
Diagnosis is COPD or exercise-induced bronchospasm	12 months
Diagnosis is moderate persistent or severe persistent asthma, or partly controlled or uncontrolled asthma (see classification below)	6 months
Patient scored <= 19 on Asthma Control Test™	6 months

### RESPIRATORY AGENTS: BETA-ADRENERGIC, LONG-ACTING INHALERS

STEP THERAPY REQUIRED “PREFERRED”	PA REQUIRED
FORADIL® (formoterol)	ARCAPTA NEOHALER® (indacaterol) SEREVENT DISKUS® (salmeterol)

### RESPIRATORY AGENTS: BETA-ADRENERGIC, LONG-ACTING NEBULIZER SOLUTION

STEP THERAPY REQUIRED “PREFERRED”	PA REQUIRED
	BROVANA™ (arformoterol) PERFOROMIST® (formoterol)

### RESPIRATORY AGENTS: BETA-ADRENERGIC COMBINATIONS

STEP THERAPY REQUIRED “PREFERRED”	PA REQUIRED
ADVAIR DISKUS® and HFA (salmeterol/fluticasone) DULERA® (formoterol/mometasone) SYMBICORT® (formoterol/budesonide)	



## Respiratory Agents: Epinephrine Auto-Injectors

**LENGTH OF AUTHORIZATIONS:** 1 year

The requested medication may be approved if there has been therapeutic failure using the product(s) not requiring prior approval.

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medication(s) not requiring prior approval
- Contraindication to or drug interaction with medication(s) not requiring prior approval
- History of unacceptable/toxic side effects to medication(s) not requiring prior approval

### **RESPIRATORY AGENTS: EPINEPHRINE AUTO-INJECTORS**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
AUVI-Q™ (epinephrine) EPIPEN® (epinephrine) EPIPEN JR® (epinephrine)	

## Respiratory Agents: Glucocorticoid Agents – Inhaled

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
  - Patient’s condition is clinically unstable--patient has had an ER visit or at least two hospitalizations for asthma in the past thirty days--changing to a medication not requiring prior approval might cause deterioration of the patient’s condition.
2. If there have been therapeutic failures to no less than one-month trials of at least two medications not requiring prior approval, then may approve the requested medication.

**ADDITIONAL INFORMATION TO AID IN THE FINAL DECISION**

If the patient is a child under 13 years old or a patient with a significant disability, and unable to use an inhaler which does not require prior approval, or is non-compliant on an inhaler not requiring prior approval because of taste, dry mouth, infection; then may approve the requested medication.

**RESPIRATORY AGENTS: GLUCOCORTICOIDS – INHALED**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
ASMANEX <sup>®</sup> (mometasone) FLOVENT DISKUS <sup>®</sup> and HFA (fluticasone) QVAR <sup>®</sup> (beclomethasone)	ALVESCO <sup>®</sup> (ciclesonide) PULMICORT FLEXHALER <sup>®</sup> (budesonide)

**RESPIRATORY AGENTS: GLUCOCORTICOIDS – NEBULIZERS**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
PULMICORT <sup>®</sup> nebulizer solution (no PA required for age 8 or under) (budesonide)	BUDESONIDE nebulizer solution (generic of Pulmicort <sup>®</sup> ) PULMICORT <sup>®</sup> nebulizer solution (PA required for over age 8) (budesonide)

## Respiratory Agents: Leukotriene Receptor Modifiers and Inhibitors

**LENGTH OF AUTHORIZATIONS:** 1 year

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to medications not requiring prior approval
  - Contraindication to or drug interaction with medications not requiring prior approval
  - History of unacceptable/toxic side effects to medications not requiring prior approval
2. If there has been a therapeutic failure to the agent not requiring prior approval, then may approve the requested medication.

### **RESPIRATORY AGENTS: LEUKOTRIENE RECEPTOR ANTAGONISTS**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
MONTELUKAST tablets, chewable tablets, granules (generic of Singulair®) ZAFIRLUKAST (generic of Accolate®)	ZYFLO® (zileuton) ZYFLO CR® (zileuton)

## Respiratory Agents: Nasal Preparations

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY: GLUCOCORTICOIDS ONLY**

- 1) For a preferred brand, there must have been inadequate clinical response to preferred generic alternatives, including a trial of no less than one month of at least one preferred generic
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month each of at least two preferred generics or brands

**OTHER CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**RESPIRATORY AGENTS: NASAL PREPARATIONS - GLUCOCORTICOIDS**

NO PA REQUIRED "PREFERRED GENERIC"	STEP THERAPY REQUIRED "PREFERRED BRAND"	PA REQUIRED
FLUNISOLIDE FLUTICASONE (generic of Flonase®) NASACORT® AQ (triamcinolone)	NASONEX® (mometasone)	BECONASE® AQ (beclomethasone) DYMISTA® (fluticasone/azelastine) OMNARIS® (ciclesonide) QNASL® (beclomethasone) RHINOCORT AQUA® (budesonide) TRIAMCINOLONE (generic of Nasacort® AQ) VERAMYST™ (fluticasone furoate) ZETONNA® (ciclesonide)

**RESPIRATORY AGENTS: NASAL PREPARATIONS - ANTIHISTAMINES**

	PA REQUIRED
ASTELIN® (azelastine) ASTEPRO® (azelastine) PATANASE® (olopatadine)	AZELASTINE (generic of Astelin®)

**RESPIRATORY AGENTS: NASAL PREPARATIONS - ANTICHOLINERGICS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
IPRATROPIUM (generic of Atrovent®)	

## Topical Agents: Acne Preparations

**LENGTH OF AUTHORIZATIONS:** 1 year

**CLINICAL CRITERIA:**

All topical retinoids require prior authorization for patients over age 23:

- Patient diagnosis psoriasis – may approve tazarotene (Tazorac<sup>®</sup>)
- Patient diagnosis acne vulgaris – may approve retinoid if the patient has a history of at least 30 days of therapy with alternative therapy (benzoyl peroxide, sodium sulfacetamide or antibiotic) in the previous 90 days
- Patient diagnosis skin cancer – may approve retinoid

**PDL CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**ADDITIONAL INFORMATION**

The requested medication may be approved if the following is true:

- If there has been a therapeutic failure to no less than a one-month trial of at least one medication in the same class not requiring prior approval

**ANTIBIOTIC PRODUCTS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CLINDAGEL <sup>®</sup> (clindamycin) CLINDAMYCIN gel (generic of Cleocin T <sup>®</sup> , Clindamax <sup>®</sup> ) CLINDAMYCIN lotion (generic of Cleocin T <sup>®</sup> , Clindamax <sup>®</sup> ) CLINDAMYCIN solution (generic of Cleocin T <sup>®</sup> ) ERYTHROMYCIN gel ERYTHROMYCIN solution (generic of A/T/S <sup>®</sup> , Akne-Mycin <sup>®</sup> )	AKNE-MYCIN <sup>®</sup> ointment (erythromycin) CLINDACIN <sup>®</sup> Pak (clindamycin/skin cleanser kit) CLINDAMYCIN foam (generic of Evoclin <sup>®</sup> ) CLINDAMYCIN pledgets (generic of Cleocin T <sup>®</sup> ) ERY PADS <sup>®</sup> (erythromycin)

**ACNE PREPARATIONS – OTHER PRODUCTS**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
AZELEX <sup>®</sup> cream (azelaic acid)	ACZONE <sup>®</sup> gel (dapsone) FINACEA <sup>®</sup> gel (azelaic acid) FINACEA PLUS <sup>®</sup> kit (azelaic acid)

### BENZOYL PEROXIDE AND COMBINATION PRODUCTS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CLINDAMYCIN-BENZOYL PEROXIDE gel (generic of Benzaclin <sup>®</sup> )	ACANYA <sup>®</sup> (clindamycin-benzoyl peroxide)
BENZOYL PEROXIDE cleanser (generic of Oscion <sup>®</sup> , Triaz <sup>®</sup> )	BENZAMYCINPAK <sup>®</sup> gel (benzoyl peroxide and erythromycin)
BENZOYL PEROXIDE gel (generic of Benzac AC <sup>®</sup> , Brevoxyl <sup>®</sup> , Desquam-X <sup>®</sup> , Panoxyl <sup>®</sup> )	BENZEFOAM <sup>®</sup>
BENZOYL PEROXIDE wash (generic of Benzac AC <sup>®</sup> , Benzac W <sup>®</sup> , Brevoxyl <sup>®</sup> , Desquam-X <sup>®</sup> , Pacnex <sup>®</sup> )	BENZOYL PEROXIDE MICROSPHERES wash (generic of Neobenz Micro <sup>®</sup> )
ERYTHROMYCIN-BENZOYL PEROXIDE gel (generic of Benzamycin <sup>®</sup> )	BENZOYL PEROXIDE pads (generic of Oscion <sup>®</sup> , Triaz <sup>®</sup> )
PANOXYL <sup>®</sup> 10% foam, wash (benzoyl peroxide)	BENZOYL PEROXIDE-ALOE VERA wash (generic of Benziq <sup>®</sup> wash)
	CLINDAMYCIN-BENZOYL PEROXIDE gel (generic of Duac <sup>®</sup> )
	DUAC CS <sup>®</sup> gel (benzoyl peroxide and clindamycin)
	INOVA EASY PAD <sup>®</sup> (benzoyl peroxide)
	PACNEX HP <sup>®</sup> (benzoyl peroxide)
	PACNEX LP <sup>®</sup> (benzoyl peroxide)
	PACNEX MX <sup>®</sup> (benzoyl peroxide)

### RETINOID AND COMBINATION PRODUCTS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
DIFFERIN <sup>®</sup> cream, gel, lotion (adapalene)	ADAPALENE cream, gel (generic of Differin <sup>®</sup> )
RETIN-A MICRO <sup>®</sup> gel (tretinoin)	ATRALIN <sup>®</sup> gel (tretinoin)
TAZORAC <sup>®</sup> cream, gel (tazarotene)	EPIDUO <sup>®</sup> gel (adapalene/benzoyl peroxide)
TRETINOIN cream, gel (generic of Retin-A <sup>®</sup> )	VELTIN <sup>®</sup> gel (clindamycin/tretinoin)
	ZIANA <sup>®</sup> gel (clindamycin/tretinoin)

### SODIUM SULFACETAMIDE AND COMBINATION PRODUCTS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
KLARON <sup>®</sup> lotion (sulfacetamide)	CLARIFOAM EF <sup>®</sup> emollient foam
SODIUM SULFACETAMIDE-SULFUR wash (generic of Avar <sup>®</sup> cleanser, Clenia <sup>®</sup> foaming wash, Plexion <sup>®</sup> cleanser, Rosac <sup>®</sup> wash)	CLENIA emollient cream
	SODIUM SULFACETAMIDE lotion (generic of Klaron <sup>®</sup> )
	SODIUM SULFACETAMIDE-SULFUR pads (generic of Plexion <sup>®</sup> cleansing cloths)
	SODIUM SULFACETAMIDE-SULFUR-UREA cleanser (generic of Rosula <sup>®</sup> cleanser)
	SODIUM SULFACETAMIDE-SULFUR-UREA wash (generic of Rosula <sup>®</sup> clarifying wash)
	SODIUM SULFACETAMIDE-SULFUR-WITCH HAZEL cream (generic of Plexion <sup>®</sup> SCT cream)
	SULFACETAMIDE SODIUM-SULFUR topical suspension (generic of Sumaxin TS <sup>®</sup> )

## Topical Agents: Androgens

**LENGTH OF AUTHORIZATIONS:** 1 year

The requested medication may be approved if there has been a therapeutic failure to no less than a three-month trial of all medications not requiring prior approval.

Is there any reason the patient cannot be changed to a medication not requiring prior approval?  
Acceptable reasons include:

- Allergy to all medications not requiring prior approval
- Contraindication to or drug interaction with all medications not requiring prior approval
- History of unacceptable/toxic side effects to all medications not requiring prior approval

### **ADDITIONAL INFORMATION**

Limited to males  $\geq$  18 years

### **TOPICAL AGENTS: ANDROGENS**

<b>NO PA REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
ANDRODERM <sup>®</sup> patch (testosterone) ANDROGEL <sup>®</sup> (testosterone)	AXIRON <sup>®</sup> gel (testosterone) FORTESTA <sup>®</sup> gel (testosterone) TESTIM <sup>®</sup> gel (testosterone)

## Topical Agents: Anti-Fungals

**LENGTH OF AUTHORIZATIONS:**      Duration of the prescription (up to 6 months)

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
  - Allergy to at least two medications not requiring prior approval
  - Contraindication to all medications not requiring prior approval
  - History of unacceptable/toxic side effects to at least two medications not requiring prior approval
2. Is the infection caused or presumed to be caused by an organism resistant to medications not requiring prior approval?
3. Has the patient failed therapeutic trials of two weeks with two medications not requiring prior approval?

### TOPICAL AGENTS: ANTI-FUNGALS

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CICLOPIROX cream, gel, topical suspension, shampoo (generic of Loprox <sup>®</sup> )	CICLOPIROX kit (generic of CNL <sup>®</sup> Nail lacquer kit)
CICLOPIROX solution (generic of Penlac <sup>®</sup> )	ERTACZO <sup>®</sup> (sertaconazole)
CLOTRIMAZOLE (generic of Lotrimin <sup>®</sup> )	EXELDERM <sup>®</sup> (sulconazole)
CLOTRIMAZOLE/BETAMETHASONE (generic of Lotrisone <sup>®</sup> )	KETOCONAZOLE foam (generic of Extina <sup>®</sup> )
ECONAZOLE (generic of Spectazole <sup>®</sup> )	MENTAX <sup>®</sup> (butenafine)
KETOCONAZOLE Cream & Shampoo (generic of Kuric <sup>®</sup> , Nizoral <sup>®</sup> )	NAFTIN <sup>®</sup> (naftifine)
MICONAZOLE	OXISTAT <sup>®</sup> (oxiconazole)
NYSTATIN	PEDI-DRI <sup>®</sup> powder (nystatin)
NYSTATIN/TRIAMCINOLONE	PEDIADERM AF <sup>®</sup> cream (nystatin)
TERBINAFINE (generic of Lamisil <sup>®</sup> )	VUSION <sup>®</sup> ointment (miconazole/zinc)
TOLNAFTATE (generic of Tinactin <sup>®</sup> )	XOLEGEL <sup>™</sup> (ketoconazole)

## Topical Agents: Anti-Parasitics

**LENGTH OF AUTHORIZATIONS:** 2 weeks

Is there any reason the patient cannot be changed to a medication not requiring prior approval?  
Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

### **ADDITIONAL INFORMATION**

The requested medication may be approved if the following is true:

- If there has been a therapeutic failure to no less than a one-month trial of at least one medication not requiring prior approval
- The requested medication's corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.

### **INDICATIONS AS APPROVED BY FDA**

- Benzyl alcohol lotion is indicated for patients 6 months of age and older
- Crothamiton is indicated for adults
- Ivermectin is indicated for age 6 months and older
- Lindane lotion and shampoo are indicated only in patients who cannot tolerate or who have failed other treatments. **The P&T Committee does not recommend use of lindane.**
- Malathion is indicated for patients 6 years of age and older
- Permethrin cream and lotion are indicated for patients 2 months of age and older
- Spinosad is indicated for patients 4 years of age and older
- Package labeling does not list age for permethrin or piperonyl butoxide-pyrethrins

### **ANTI-PARASITICS, TREATMENT OF SCABIES**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
PERMETHRIN cream (generic of Elimite®)	EURAX® cream, lotion (crothamiton)

### **ANTI-PARASITICS, TREATMENT OF LICE**

NO PA REQUIRED "PREFERRED"	PA REQUIRED
LICE kit [piperonyl butoxide-pyrethrins shampoo, comb, permethrin home spray] (generic of Rid® complete kit)	MALATHION lotion (generic of Ovide®)
NATROBA® (spinosad)	SPINOSAD (generic of Natroba®)
PERMETHRIN lotion (generic of Nix® cream rinse)	ULESFIA® lotion (benzyl alcohol)
PIPERONYL BUTOXIDE-PYRETHRINS lotion	
PIPERONYL BUTOXIDE-PYRETHRINS shampoo (generic of Rid® shampoo)	
SKLICE® lotion (ivermectin)	



**TOPICAL AGENTS: CORTICOSTEROIDS – HIGH POTENCY**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
AMCINONIDE ointment, cream, lotion BETAMETHASONE VALERATE ointment (generic of Valisone <sup>®</sup> ) DIFLORASONE DIACETATE cream, ointment (generic of Florone <sup>®</sup> ) FLUOCINONIDE cream, gel, ointment, solution (generic of Lidex <sup>®</sup> , Lidex-E <sup>®</sup> )	APEXICON-E <sup>®</sup> (diflorasone diacetate emollient base) cream BETAMETHASONE DIPROPIONATE cream, ointment (generic of Diprolene <sup>®</sup> ) HALOG <sup>®</sup> cream, ointment (halcinonide) KENALOG <sup>®</sup> aerosol spray (triamcinolone acetonide) VANOS <sup>®</sup> cream (fluocinonide)

**TOPICAL AGENTS: CORTICOSTEROIDS – VERY HIGH POTENCY**

NO PA REQUIRED “PREFERRED”	PA REQUIRED
	BETAMETHASONE DIPROPIONATE AUGMENTED cream, ointment, lotion, gel (generic of Diprolene AF <sup>®</sup> ) CLOBETASOL PROPIONATE cream, emollient base cream, foam, gel, lotion, ointment, shampoo, solution (generic of Olux <sup>®</sup> , Temovate <sup>®</sup> ) CLOBEX <sup>®</sup> lotion, shampoo, spray (clobetasol propionate) HALOBETASOL PROPIONATE cream, ointment (generic of Ultravate <sup>®</sup> ) OLUX-E <sup>®</sup> foam (clobetasol propionate)

## Topical Agents: Immunomodulators

**LENGTH OF AUTHORIZATIONS:** 1 year

**STEP THERAPY:**

- 1) For a preferred brand, there must have been inadequate clinical response to no less than two one-month trials of topical corticosteroids
- 2) For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than one month of the preferred brand

**OTHER CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?  
Acceptable reasons include:

- Allergy to medications not requiring prior approval
- Contraindication to or drug interaction with medications not requiring prior approval
- History of unacceptable/toxic side effects to medications not requiring prior approval

**CLINICAL INFORMATION**

- Indicated for short-term and intermittent long-term treatment of atopic dermatitis if:
  - Alternative, conventional therapies (such as topical corticosteroids) are deemed inadvisable because of potential risks, or
  - There has been inadequate response or intolerance to alternative, conventional therapies (such as topical corticosteroids)
- Elidel<sup>®</sup> and Protopic<sup>®</sup> 0.03% are indicated in patients 2 years old or older. Protopic<sup>®</sup> 0.1% is indicated in adults only

**TOPICAL IMMUNOMODULATORS**

<b>STEP THERAPY REQUIRED "PREFERRED"</b>	<b>PA REQUIRED</b>
ELIDEL <sup>®</sup> * (pimecrolimus)	PROTOPIC <sup>®</sup> * (tacrolimus)

\* Elidel<sup>®</sup> & Protopic<sup>®</sup> have age restriction of 2 years or older